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Adverse drug reactions are a leading cause of morbidity and mortality that costs billions of dollars
for the healthcare system. In children, there is increased risk for adverse drug reactions with
potentially lasting adverse effects into adulthood. The current pediatric drug safety landscape,
including clinical trials, is limited as it rarely includes children and relies on extrapolation from
adults. Children are not small adults but go through an evolutionarily conserved and physiologically
dynamic process of growth and maturation. We hypothesize that adverse drug reactions manifest
from the interaction between drug exposure and dynamic biological processes during child growth
and development. While pediatric pharmacologists have studied and recognized this interaction, the
evidence from these studies have focused on a few, well-known drug toxicities largely within
animal models that have limited translation to children and their clinical care. Moreover, preclinical
studies during drug development do not consider growth and maturation of children, which severely
limits our knowledge of drug safety in this population. Post-marketing pediatric drug safety studies,
on the other hand, leverage large amounts of observations to identify and characterize adverse drug
events in the pediatric population after drugs enter the market. However, these observational studies
have been limited to event surveillance and have not focused on evaluating why adverse drug events
may manifest in children. We hypothesize that by developing statistical methodologies with prior
knowledge of dynamic, shared information during development, we can improve the detection of
adverse drug events in children. We further hypothesize that detecting adverse drug events in this
way also improves the evaluation of dynamic biological and physiological processes during child
growth and development. In chapter 1, we described the pediatric drug safety landscape, dynamic
processes from pediatric developmental biology, and motivation for a large-scale and data-driven
approach to study the interaction between drug treatment and child development. In chapter 2,
using drug event reports collected by the Food and Drug Administration (FDA), we evaluated
statistical models for identifying temporal trends of adverse effects across childhood. We found the
generalized additive model (GAM), as compared to a popular disproportionality method, show
improved detection performance especially of rare pediatric adverse drug events. In chapter 3, we
applied covariate-adjusted drug-event GAMs in a systematic way to develop a resource of nearly
half a million adverse drug event (ADE) risk estimates across child development stages. We
showed that not only do significant ADEs through childhood recapitulate dynamic organ and
system maturation, but we also provide granular, development-specific risk for known pediatric
drug effects that were previously unknown. Importantly, this approach facilitated the evaluation of
dynamic biological processes, such as drug-metabolizer gene expression levels across childhood,
that we observed coincided with dynamic risk of adverse drug effects. In chapter 4, we performed
several case studies showing population-level evidence for well-known pediatric adverse drug
reactions using our generated resource. In addition, we developed an accessible web portal, the
Pediatric Drug Safety portal (PDSportal), to retrieve from our resource the population-level
evidence of user-specified adverse drug events in the pediatric population across child development
stages. In conclusion, we summarize three key research directions in data-driven pediatric drug
safety research: quantifying child vs. adult drug safety profiles, predicting pre-clinical drug toxicity
across childhood, and detecting genetic susceptibility of pediatric adverse drug events. Our results
demonstrate that developing pediatric drug safety methods directly for children using data-driven
approaches improves both identification and evaluation of adverse drug events during the period of
child growth and development.
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Chapter 1: Introduction
The work in this chapter is adapted in part from the following publication:
Giangreco, NP, Elias, JE, Tatonetti, NP. No population left behind: Improving paediatric drug
safety using informatics and systems biology. Br J Clin Pharmacol. 2021; 1– 7. https:
//doi.org/10.1111/bcp.14705
1.1 Children and adverse drug effects
Adverse drug reactions are one of the leading causes of hospitalizations and deaths, as well
as incurring billions of dollars in direct costs to hospitals every year [1][2][3][4]. With special
populations such as children rarely eligible for trials evaluating drug efficacy and safety, there
may be a more dire impact by adverse reactions from drug treatment towards children. Millions
of children are prescribed medications every year[5][6] and adverse effects are common[7]. A
meta-analysis showed the prevalence of adverse drug effects in pediatric patients is as high as 16.8
percent and that 0.4 to 10.3 percent of hospitalizations are due to adverse drug effects[8]. Moreover,
there is evidence that children are more likely to experience adverse effects from drug treatment
leading to hospital admission and during admission as compared with adults [9]. Drugs associated to
adverse drug effects are from various drug classes, with anti-epileptic, NSAID, and antibiotic drugs
being the most frequent culprits[10][11]. Notably, the observed effects can be severe and up to 87
percent were found to be preventable[12]. Adverse drug effects can negatively impact the quality of
life of children[13], such as suffering mood and other psychiatric disorders after taking montelukast
for asthma treatment[14]. Importantly, drug exposure during childhood can lead to late-onset or
long-term adverse drug effects[15], such as ototoxicity from platinum chemotherapy[16]. Few
studies have investigated long-term effects of drug exposures outside chemotherapy making it
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difficult to anticipate the consequences of drug therapy during childhood.
1.2 Children and the drug safety landscape
Traditional methods for establishing drug safety, including preclinical studies, clinical trials,
and post-marketing surveillance, have failed the pediatric population. Safety pharmacology studies
are conducted preclinically and evaluate undesirable pharmacodynamic effects of drugs before
first-in-human trials[17]. Only recently have these studies included juvenile animal studies, which
aim to understand drug effects during early human development. Juvenile animal studies are an
attractive alternative for evaluating toxicity in a developing system, but there is doubt whether these
studies sufficiently influence drug development and the design of subsequent trials[18]. Furthermore,
juvenile animal studies cannot fully capture all stages of development and long-term effects, limiting
their applicability. A pediatric plan (either the European Pediatric Investigation Plan or US Pediatric
Study Plan) is submitted during preclinical development when the pediatric population will largely
benefit from the drug. However, whether a pediatric plan is needed is dependent on the indication,
which can result in bias for a select number of diseases and drugs[19][20]. In short, it is challenging
to assess drug safety for children during the preclinical phase.
In the next phase of drug development, clinical trials are a primary source of adverse effect
information. However, they rarely include pediatric patients even if the drug is widely used in
this population (Figure 1.1). This leads to a high prevalence of “off-label” drug prescriptions,
which can lead to avoidable adverse drug effects in children[21][22]. In response, government
regulators are increasing funding, incentives, and standards for pediatric drug development and
clinical trials[20][23][24][25][26][27]. While these regulations promote pediatric drug develop-
ment and evolve guidelines of pediatric medications[28], there is concern whether these regu-
lations are effectively addressing the needs of the pediatric population while establishing drug
safety in children[29][30][31][32]. Pediatric clinical trials suffer from low completion rates, is-
sues establishing generalizable study designs, lack of accepted and validated pediatric endpoints,
scarce participants and inflated placebo effects, and inability to detect long-term adverse drug
2
Figure 1.1: Relationship between the rate of drug prescription in an Academic Medical Center
and evaluation in clinical trials for children. All drugs prescribed clinically have been tested
within clinical trials. The percentages on the x-axis indicate the proportion of pediatric patients
(<18 years old) out of all patients prescribed a drug at Columbia University Irving Medical Center.
The y-axis indicates the proportion of pediatric clinical trials out of all clinical trials registered at
clinicaltrials.gov. The error bars represent 95% confidence intervals. The number above the bars
indicate the number of clinical trials including pediatric patients for the prescribed drugs in that
category.
effects[27][31][33][34][35]. As a result, it can take years for drug labels to be updated with pediatric
indications or safety information[36]. Additionally, the ethical conduct of pediatric clinical trials
is still a contested and unresolved subject, balancing issues such as informed consent, subject
recruitment, biological sample collection, and convenience of participation[31][37]. The clinical
trial framework is limited and insufficient in identifying and evaluating possible adverse drug effects
in children.
Post-marketing pediatric drug safety studies identify and characterize adverse drug effects in the
pediatric population after drugs enter the market. The growth of both prospective[8][11][38][39][40]
and retrospective studies[41][42][43][44] as well as aggregate studies by pediatric consortiums[45][46][47]
have dramatically increased our knowledge on the prevalence, adverse event types, and relative risks
of adverse drug effects in the pediatric population. However, a review of pediatric pharmacoepidemi-
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ology studies by the International Society for Pharmacoepidemiology (ISPE) has noted majority
of studies have almost no overlap in database used, are limited in sample size especially when
stratifying to pediatric subpopulations, and have missing data types such as parental-child links and
detailed medication information[48]. Also, pediatric pharmacovigilance studies are exploratory and
descriptive in nature[49], and have limited clinical translation due to insufficient statistical control
of bias and confounding[50]. This leads to increased false discoveries, incomplete evidence of
adverse drug effects in children compared to other populations, and limited evidence of adverse
drug effects attributed to the disease indication or stage of child development. Current pediatric drug
safety studies insufficiently characterize the manifestation of adverse drug effects during childhood.
1.3 Why adverse drug effects manifest in children
During preclinical drug development, juvenile animals are used to evaluate evidence of drug
disposition (e.g. drug absorption, distribution, metabolism, and excretion) during growth and
development. Between 2007 and 2014, there were 44 pediatric clinical drug trial failures, where
the two major factors were (i) not considering differences in adult and pediatric disease and (ii)
inappropriate dosing due to variable drug disposition in young children[34]. In fact, these factors
are widely recognized and codified into the Food and Drug Administration (FDA) drug safety
legislation: drug safety can be extrapolated from adults to children if 1) the disease is determined to
be similar and 2) the effect of the drug is similar between adults and children[51]. On the contrary,
children are not simply small adults[52][53][54] but can have distinct disease pathogenesis and
trajectory[55]. Rapid growth and development during the period from birth through the teenage
years complicates drug treatment when disease manifests. For instance, a child with cancer has
a more complicated chemotherapeutic regimen than an adult because of the need to account for
long-term adverse effects on the hypothalamic-pituitary-adrenal axis and growth[56]. We can
improve drug safety in the pediatric population by understanding biological processes during growth
and development.
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1.4 Pediatric biology and ontogenic mechanisms
Unlike adults, children undergo dynamic biological and physical processes from accelerated
growth and maturation[57]. Children undergo an evolutionarily conserved process of genomic
imprinting, hormonal regulation, and adaptive phenotype trajectories across the stages of devel-
opment[58]. The obvious physical changes as children grow older are reflections of rapid and
dynamic organ development, tissue differentiation, and functional development across childhood.
For example, the transition from placental circulation to the circulatory self-reliance after birth
comprises numerous and meticulously orchestrated cardiovascular adaptations, including cardiac
progenitor hypertrophy and transcription programs, that can cause fatal implications if disrupted
[59]. The human fovea in the retina forms dense cones and elongated rod axons after birth reaching
mature levels around 10 years old [60]. The auditory capacity and speech discrimination increases
dramatically in the first year of life reaching full expression between 5 and 10 years of age [61].
The immune system dynamically develops where immune cells and immunoglobulins vary in
number and concentration across many years ultimately converging to adult levels[62][63][64]. The
human brain is constantly changing, from increasing and decreasing white and gray matter through
adolescence[65][66], growth and elimination of synapses and neurons[67], and adaptive expression
of receptors and neurotransmitters from early life through adolescence[68]. One of the most fasci-
nating and possibly influential processes in human biology stems from our endocrine system, and in
childhood different hormones coordinated by the developing brain regulate tissue differentiation,
cell proliferation, and receptor expression during the different stages of development[58][69][70].
Advances in large-scale genomic technologies, as well as international collaborations such as the
Pediatric Cell Atlas[71], allow researchers to probe and illuminate the molecular landscapes that
are a reflection of this developmental period[72][73]. A multi-omics perspective of the first week of
life showed distinct molecular networks and pathways, such as increasing interleukin signaling and
complement cascade, characterizing a stable developmental trajectory since birth[74]. Stevens et
al. highlighted the developing molecular landscape across childhood, showing clusters of genetic
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programs toward each phase of growth including dynamics of signaling pathways across growth
phases such as NOTCH, TFGB, and VEGF signaling[75]. Moreover, concerted gene regulatory
programs are conserved across species, which is exemplified by distinct developmental trajectories
in parallel with stages of child development from the mouse liver transcriptome[76]. Distinct and
evolutionarily conserved biological mechanisms during the period of growth and development may
distinguish drug effects between children from adults.
1.5 Developmental influences on pediatric drug safety
Prenatally, perinatally, and postnatally, the response and effect of drug treatment coincides
with the dynamic molecular patterns underlying physiological and structural development in chil-
dren[77][78][79][80][81][82]. For example, linear and nonlinear dynamics of cytochrome P450 and
other metabolic enzymes influence drug disposition such as antipyrine[83], fentanyl[84], pheny-
toin[85], and many other drugs[86]. Across child developmental stages, growth and maturation
processes such as growth rates of immune and neural cell types may alter drug pharmacodynamics
as well, resulting in hypersensitivity to NSAIDS such as ibuprofen[87][88], antiepileptic drugs such
as phenobarbital[89], and drugs like warfarin and cyclosporin[90][91]. The hypothalamus-pituitary-
adrenal (HPA) axis, which secretes growth hormone and sex steroids, accelerates during puberty[92]
and may affect drug response[93][94] and be effected by drug therapy[95]. This is an example
where drug toxicity may depend on growth and maturation processes during development stages
as well as from previous developmental stages, such as during early life[96][97][98], resulting in
known but less characterized long-term drug effects[99][100][101][102]. Another less characterized
but observed phenomenon is how dynamic growth processes interact with pharmacogenes during
childhood[103]. Adverse drug effects manifest from disrupting gene variation, leading to hearing
loss[104], and altered gene expression profiles, leading to teratogenicity[105]. Genetic variation
within pharmacogenes across childhood has been established [106] but the impact on adverse drug
effects across development is largely unexplored. These and other effects during childhood, such as
drug interactions[107], emphasize the basis for and importance of uncovering pharmacodynamic
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determinants of adverse drug effects in the pediatric population.
Despite strong evidence for molecular dynamics across child development and notable drug
safety examples, such as doxorubicin-induced cardiotoxicity[108] and methylphenidate-induced
mental disorders[99], the role of child development in pediatric drug effects remains largely a
mystery. Preclinically, it is unclear if toxicity studies assess effects on child growth and development
and significantly influence the design of trials involving children[18]. When pediatric trials are
conducted (recently incentivized or required by regulation[23]), the studies include few patients
in specific age groups within too short of a time period to sufficiently evaluate drug effects during
child development[32]. This landscape is enabled by current drug safety legislation: drug safety
can be extrapolated from adults to children if 1) the disease is determined to be similar and 2)
the effect of the drug is similar between adults and children[51]. On the contrary, children are
not simply small adults[52][53][54] but can have distinct disease pathogenesis and trajectory[55].
Rapid growth and development during the period from birth through the teenage years complicates
drug treatment when disease manifests. The pediatric drug safety landscape requires a large-scale
approach, including the entire pediatric population, to contextualize the maturation and development
of this diverse population.
1.6 Data-driven pediatric drug safety
Real-world observational data, such as from spontaneous reports and electronic health record
databases, can identify a diverse range of drug effects in large pediatric populations across different
growth and development contexts[109]. Importantly, observational studies can identify idiosyncratic
but clinically-relevant risks of medications taken throughout childhood[110]. Notwithstanding
the need to mitigate substantial bias inherent in real-world pediatric data, statistical and machine
learning approaches can address this challenge and investigate the interaction between prescribed
medications, observed side effects, and the developmental context of children. For newborns to
young adults, and for those with diseases both common and rare, real-world observational data
presents an opportunity to systematically investigate drug safety in the context of child development.
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Current real-world observational data approaches in pediatric drug safety treat child development
as independent periods of time instead of a continuous trajectory throughout childhood. The
proportional reporting ratio (PRR), a disproportionality statistic of event prevalence associated with
drug exposure, is commonly used by researchers and agencies to identify adverse drug events in
the pediatric population. However, disproportionality statistics are limited to either modeling all
children as one homologous group or to modeling risks within age groups which limits their power
and treats children as distinct and unrelated to their similarly developing peers[111]. The advantage
of the PRR is not having assumptions on how the data is generated. However, the disadvantages
include lower ability to detect true associations when data is limited and there is no way to estimate
risk at different development stages if there are no direct observations. An alternative approach is to
model the association of age to the occurrence of an adverse drug event. Even so, the assumptions
upholding linear models are violated which increases the occurrence of false discoveries and results
in poor generalization from one data source to another. In this thesis and associated manuscripts,
we show that generalized additive models (GAMs) address these limitations and generate robust
and sensitive scores for modeling temporal adverse drug event risk across childhood[112]. GAMs
allow for sharing information between development stages to reveal drug effect dynamics even
when there may be scant evidence at a particular stage. Moreover, GAMs share information across
development stages especially at adjacent stages, which is a desired model assumption considering
variation in development from extrinsic and intrinsic factors. Although GAMs are computationally
less efficient and time intensive, modern computing including parallelization can overcome these
limitations to effectively share information across stages to increase power (Figure 1.2).
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Figure 1.2: Strategies to associate the effect of age on the occurrence of adverse drug events.
Advantages and disadvantages of disproportionality statistics, linear models, and generalized
additive models in age effect estimation of adverse drug event occurrence.
1.7 Thesis overview
I argue that detecting and evaluating pediatric adverse drug events is improved using statistical
and data-driven approaches that share information across the stages of child development. In chapter
2, I develop a logistic generalized additive model to detect dynamic adverse drug event reporting and
evaluate its performance in comparison to the popular disproportionality method used in pediatric
drug safety. In chapter 3, I develop covariate-adjusted drug-event GAMs and systematically
generate hypotheses of dynamic adverse drug event risk that correspond with dynamic biological
and physiological processes across child development stages. In chapter 4, I provide in-depth case
studies, as well as deploy a publicly accessible web portal, of the evidence for clinically-relevant
pediatric adverse drug events using the database resource generated in chapter 3. I conclude by
discussing three key research directions in data-driven pediatric drug safety that builds and extends
on this body of work.
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Chapter 2: Evaluating risk detection methods to uncover
ontogenic-mediated adverse drug effect mechanisms in children
The work in this chapter is adapted in part from the following publication: Giangreco, N.P.,
Tatonetti, N.P. Evaluating risk detection methods to uncover ontogenic-mediated adverse drug
effect mechanisms in children. BioData Mining 14, 34 (2021). https://doi.org/10.
1186/s13040-021-00264-9
2.1 Introduction
Adverse drug events (ADEs) in children are common and can result in injury and death[7][8].
Clinical trials rarely include children[110] and pediatric-specific trials are limited in identifying
possible ADEs in the population[32]. Pediatric drug safety studies can evaluate large numbers
of ADEs from the population[113] but current methodologies are limited in their ability to iden-
tify the mechanisms that drive pediatric ADEs[50]. Children undergo evolutionarily conserved
and physiologically dynamic biological processes, collectively called ontogeny, as they grow and
develop from birth through adolescence[58][114]. The mechanisms may include varying protein
activity[115][116] as well as include functional and structural changes that occur during matu-
ration[117][63]. These ontogenic changes can alter pharmacodynamics and pharmacokinetics
resulting in adverse effects, as is the case for doxorubicin-induced cardiotoxicity[118] and valproate-
induced hepatotoxicity[119]. With a few notable exceptions, however, many pediatric adverse events
are idiopathic with no known, clear connection to developmental biology[120][93]. Additionally,
adverse event mechanisms established in adults may not translate to the pediatric population[121].
There is an opportunity to combine known ontogenic biology with real-world pediatric drug effect
data to identify ontogenic-mediated adverse events.
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To date, elucidation of ontogenic mechanisms has relied on hypothesis-driven approaches. For
example, juvenile mouse models have been used to identify genetic vulnerabilities of hematopoiesis[122]
and investigate effects by a glutamatergic agonist on the neural developmental sequence[123] during
early life. More recently, pharmacometric tools have been used to extrapolate drug effects from
adults to children, such as projecting acetaminophen exposure across pediatric age groups[124], and
investigate drug action in children, such as predicting clearance of zidovudine during infancy[125].
However, juvenile animal studies are low-throughput and require complex study designs[18],
and there is limited experimental data to parameterize manually designed pharmacometric mod-
els[126][127]. While lacking specificity, top-down studies are complementary in that they evaluate
thousands of hypotheses simultaneously and can identify idiosyncratic effects that would otherwise
go unnoticed[109][128]. Moreover, analyses of large population datasets start from clinically
significant events which can take decades to identify[129][130]. Top-down studies can close the
pediatric evidence gap[126] by sifting through large databases to identify clinically significant
although perhaps less studied and rare adverse drug events during the period of child growth and
development.
While pediatric pharmacovigilance has been able to identify adverse drug events, it is limited
in identifying growth and development processes that underlie those observations[116][131]. A
common approach when identifying ADEs is to stratify the pediatric population into age groups.
The Proportional Reporting Ratio, which was designed to be sensitive even when data is scarce[132],
is an established detection method and has been shown to unmask ADE signal within child de-
velopment stages compared to detection within the larger pediatric population[45]. However, this
common practice in pediatric drug safety directly reduces the amount of data available to identify
ADEs during childhood. Reduced data within these strata was shown to significantly affect PRR
detection performance across pediatric age groups[45]. In contrast to population stratification, the
continuous, time-dependent biological processes during growth and development suggest using all
information across child development stages to identify pediatric ADEs.
Generalized additive models (GAMs) are supervised machine learning approaches that can
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quantify non-linear effects reflective of natural phenomena[133]. GAMs may be able to quantify
signal reflecting dynamic, continuous processes such as ontogeny. These models are extensively
used for spatial and temporal analysis in ecological studies[134], such as explaining cardiovascular
mortality risk from heat waves over time[135] and rat infestation from environmental factors within
geographic areas[136]. Similar to evaluating ecological responses using shared information across
time or space, we can evaluate adverse events from temporally-connected ontogenic processes using
shared information across child development stages.
Our study evaluates the novel application of the GAM in modeling age groups in the pedi-
atric population to detect co-occurring and possibly dynamic adverse drug event reporting across
childhood. We performed a data simulation and augmentation study that 1) simulated drug event
reporting temporal trends of different effect sizes and shapes, 2) augmented existing pediatric drug
event data by inserting the simulated reporting rates within observational data, and 3) evaluated pop-
ulation stratification (PRR) and modeling (GAM) methods to detect these injected ADE reporting
dynamics. We found the detection scores generated by the GAM showed improved risk estimates
and increased detection of drug event reporting among the various simulated dynamics compared to
the PRR. Detection methods that capture temporal adverse drug event dynamics within observational
databases can improve our understanding of the interactions between child developmental biology
and adverse drug effects.
2.2 Results
2.2.1 FAERS
Our study evaluates population stratification versus modeling statistical methods to detect co-
occurring adverse events and drugs in the FDA Adverse Event Reporting System (FAERS). There
were 339,741 pediatric drug event reports in FAERS, which contained 519,555 unique drug-event
pairs. We constructed positive and negative sets of drug-events to evaluate detection of putative
dynamic drug event reporting. We randomly sampled 500 drug-event pairs to be augmented with
simulated drug event reporting dynamics, representing our positive control set for drug-events with
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putative dynamics. We then randomly sampled another 10,000 complementary drug-event pairs
where the underlying data was untouched, representing our negative control set of drug-events with
no known dynamics. We showed there was no significant difference in the amount of drug-event
reporting between FAERS and the negative control (2-sample Student t-test p-value = 0.98) pairs
(Fig. 2.1).
Figure 2.1: Comparison of drug event reporting in drug-event datasets. A boxplot summary
overlayed by the amount of drug event reports for drug-event pairs between (pediatric) FAERS (N =
519,555), the positive control set (N = 500), and the negative control set (N = 10,000). ‘N’ is the
sample size.
2.2.2 Data simulation and augmentation
We augmented the 500 drug-event pairs in the positive control set with putative drug event
dynamics (see Methods). Augmenting the positive control data with drug event reporting dynamics
did not have a systematic effect on the amount of drug event reporting compared to the untouched
negative control set (see Figure 2.9). However, applying the PRR and GAM detection methods onto
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the positive control data showed the generated risk scores reflected the simulated dynamics classes
(Figure 2.2).
Figure 2.2: ADE detection method risk score distribution across child development stages.
Risk scores resulting from applying the A) GAM and B) PRR ADE detection methods on the
positive control drug-event pair data of each dynamics class. The score distributions at each child
development stage were produced after 100 bootstraps of the original scores for each method and
score type. We show the average difference of the resampled score distributions between a given
drug event reporting dynamics class and uniform (random drug event reporting across childhood)
with the 95% confidence interval.
We evaluated the drug event risk scores of each detection method in reflecting the putative drug
event reporting dynamics. The GAM generated all finite and nonzero ADE risk that resembled
normally distributed scores (Shapiro-Wilk test average p-value and 95% confidence interval: 0.56
[0.12, 0.98], 90mse: 0.34 [0.023, 0.83]) in comparison to the PRR (score: 0.04 [1.29E-10, 0.22],
90mse: 0.14 [8.06E-10, 0.78]) at child development stages (Figure 2.3A). Moreover, 47% of PRR
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scores were zero and 18% were unable to be computed, on average, for drug-event pairs (Figure
2.3B).
Figure 2.3: Summary of ADE detection method risk score quality. A) Deviation from the
normal score distributions for each method and score type across development stages. The score
distributions were produced after 100 bootstraps of the original scores at each child development
stage. The Shapiro-Wilk test calculated a significance probability value for the resampled scores
being drawn from a normal distributions. B) PRR detection method risk score quality summary.
Across the positive and negative controls as well as drug event reporting dynamics classes, we
calculated the number of scores with a zero, NaN (unable to be computed; the drug not reported at
a stage or the drug not reported with the event at a stage), or nonzero positive score across child
development stages.
2.2.3 ADE dynamics detection performance
We compared the performance of the GAM and PRR for detecting drug event reporting dynamics.
Additionally, we further investigated the performance contribution at each child development stage
within the dynamics class. We found that the GAM had higher AUROC and power across stages
(Fig. 2.4 and see Figure 2.10) and similar performance within each child development stage (Figure
2.5 and see Figure 2.11) when detecting drug event reporting dynamics compared to the PRR.
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Figure 2.4: GAM and PRR drug event dynamic detection score performance. A The receiver
operating characteristic curves showing the true positive rate versus the false positive rate for
each method by drug event reporting dynamics class. The B area under the receiver operating
characteristic curve (AUROC), power (i.e. sensitivity or true positive rate, positive predictive value
(i.e. precision), and negative predictive value across child development stages for each dynamic
class.
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Figure 2.5: GAM and PRR drug event dynamic detection score performance for each child
development stage. The A) area under the reciever operating characteristic (AUROC) curve, the
B) True positive rate (i.e. power or sensitivity), the C) Positive predictive value (i.e. precision), and
the D) Negative preedictive value within each dynamics class.
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When considering low reporting of drug-events, the GAM had substantially higher AUROC and
power, at the expense of excess false positives, compared to the sensitive-by-design PRR (Figure
2.6 and see Figure 2.12).
Figure 2.6: GAM and PRR drug event dynamic detection score performance at low drug
reporting. The area under the receiver operator characteristic (AUROC) curve, the True positive
rate (i.e. power) or sensitivity, the positive predictive value (i.e precision), and the negative
predective value for with a given amount of drug reports.
2.2.4 ADE dynamics sensitivity analysis
We investigated the detection of drug event reporting across all dynamics while removing drug
reports within child development stages (see Figure 2.13 and Methods). The ADE risk scores
generated by the GAM showed dependent, flexible risk estimates across child development stages
unlike the PRR (see Figure 2.14). We found that the GAM had more robust and higher overall
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performance and sensitivity (Figure 2.7 and see Figure 2.15) to detect the various drug event
reporting dynamics as adverse events became rare at child development stages.
Figure 2.7: GAM and PRR drug event dynamic detection score performance as drug reports
become more rare. The drug reporting drug-event pairs was reduced at 10% decrements only
within a specific child development stage. For example, 0% drug reporting reduction indicates
no reduction in drug reporting and 100% drug reporting reduction indicates all drug reports were
removed. The area under the receiver operating characteristic (AUROC) curve, the power (i.e. true
positive rate or sensitivity), the positive predictive value (i.e. precision), and the negative predictive
value as drug reports become rare at child development stages.
2.2.5 Real-world validation
We conducted real-world validation to evaluate ADE risk detection against a manually curated
reference set of pediatric adverse drug events. We compared the performance of the GAM and PRR
for detecting drug-event pairs in a real-world pediatric reference set of 26 drug-event pairs (see
Methods and Figure 2.16). We found that the GAM had slightly improved overall performance
and sensitivity compared to the PRR for detecting pediatric adverse drug events (Table 2.1 and see
Figure 2.17). Moreover, we found no difference in the fraction of drug-event pairs with significant
ADE risk at child development stages (Table 2.2; proportion test p-value = 0.39). We found that the
GAM identified two real-world pediatric drug events with putative dynamic ADE risk (Figure 2.8).
Specifically, the GAM showed periods of lower risk during early and late childhood and higher risk
during the middle stages of childhood. While the PRR and GAM performed approximately the
same overall, the GAM captured dynamic ADE risk where the PRR did not.
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Figure 2.8: GAM and PRR detection scores on putative real-world dynamic adverse drug
events. We highlight two psychiatric adverse events, A Paranoia and B Affective Disorder, from
exposure to the drug montelukast exhibiting dynamic ADE risks across child development stages.
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Table 2.1: Real-world pediatric drug-event detection performance. The area under the receiver
operating characteristic curve (AUROC) and sensitivity or true positive rate to detect real-world
pediatric drug-events observed within FAERS per each method and score type. The prediction
threshold for the sensitivity was the null statistic for each method (null threshold: GAM==0;
PRR==1). The performance interval is the 95% confidence interval.
Table 2.2: ADE detection method risk score quality and significance on real-world pediatric
drug-events. The number of drug-event pairs that contained a child development stage with a risk
t2:2 score of each score quality (null threshold: GAM==0; PRR==1). A 90% lower bound score
above the null threshold indicates a significant risk.
2.3 Discussion
We present the first study to evaluate methods to detect drug event reporting patterns across child-
hood in large observational data. Children undergo a period of dynamic growth and development,
presenting a challenge in identifying and evaluating adverse drug events[137]. We hypothesize that
dynamic ontogenic processes as children grow and develop may be reflected by temporal drug event
reporting in the population. We found that GAMs, a population modeling technique, outperformed
the PRR, a population stratification method, as well as generated robust risk scores to detect adverse
drug events during childhood. This work represents a first step in transitioning from performing
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event surveillance towards uncovering putative mechanisms of pediatric adverse drug events.
The goal of our study is to improve the specificity of top-down data mining for generating
pediatric drug safety hypotheses. We hypothesized that temporal drug event reporting trends found
in observational data are dependent on ontogeny, which exhibits high and low molecular and
physiological levels throughout childhood[58][138][76]. To test this within a top-down approach,
we generated temporal trends in observational data to correspond with putative temporal trends from
ontogeny as opposed to identifying temporal trends from confounded frequency[139] or feature-
derived[140][141] measures. This motivated both simulating dynamic drug event reporting rates
and then augmenting real-world data to generate different classes of dynamic drug event reporting
trends. While we simulated dynamic drug event reporting rates, we showed that augmenting the
FAERS data did not change the overall characteristics of the pediatric drug reports. This was
crucial for establishing the use of real-world drug event data to evaluate hidden dynamic reporting
trends. Importantly the ADE detection methods were in fact able to identify the simulated dynamics
within the data. The data simulation and augmentation of FAERS laid the foundation for evaluating
statistical methods to investigate ontogenic-mediated adverse event mechanisms.
We found that the generalized additive model (GAM) showed improved detection of dynamic
drug event reporting compared to the proportional reporting ratio (PRR). While the PRR produced
ADE risk scores that were more erratic and unable to be computed, the GAM scores were more
flexible and robust. The GAM assumes a flexible relationship yet reduces ‘wiggliness’ to stable
risk estimates based on observed data[142][143]. While bayesian modeling techniques such as
Monte Carlo Markov Chain can also learn flexible relationships from observed data, these models
still require expert knowledge to build, implement, and interpret[144]. The GAM, on the other
hand, generates an interpretable smooth relationship in a familiar regression framework[133] that
shares information across child development stages. Using this shared information framework,
the GAM was able to detect injected dynamic ADE risks across childhood even when drug event
reporting was low. We further showed that the GAM not only generated visually dynamic ADE
risk when injecting dynamics (Figure 2.18A), but we also identified putative dynamic risk for
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real-world psychiatric adverse events from exposure to montelukast medication (Figure 2.18B). We
demonstrated that GAMs can be used to detect dynamic reporting of adverse drug events by sharing
information across child development stages.
Our study highlighted when sharing information resulted in the GAM performing well, including
the method’s limitations. We found that detecting drug event report dynamics overall was at least
similar if not improved for risk scores, with slightly reduced advantages by the more conservative
90% lower bound scores. Interestingly, at stages that did not have reports of a drug and event
co-occurring, the GAM showed substantial power to detect dynamics using information from
adjacent stages. However, increased detection often came at the expense of higher false positives
for the GAM especially at low reporting. Moreover, removing drug reports significantly reduced
the ability of the PRR to detect dynamics with larger uncertainty compared to the GAM (Figure
2.19). Overall, we argue the benefits afforded by the GAM, namely robust, flexible risk estimates at
small data and increased sensitivity, presents an opportunity for biologically-inspired data mining
for detecting often rare pediatric adverse events.
This study has limitations. First, observational data has inherent bias and confounding factors
which may affect both the sample of drug-event pairs in our study as well as the performance of the
detection methods. We showed that the random sample of drug events correspond to the reporting
patterns found in the FAERS database. Also, performing a power analysis allowed for identifying
drug events for which the detection methods were able to identify the dynamic reporting to provide
a fair performance comparison. Second, other regulatory agencies, such as the Food and Drug
Administration and European Medicines Agency, define pediatric age ranges for development stages
by different methods. While varying child stage definitions were not explored here, we chose stages
defined by NICHD that were established after consultation and agreement among several US-based
organizations such as the American Academy of Pediatrics and the Centers for Disease Control and
Prevention[145]. Third, fixed development stages may serve more useful in drug regulations and
trial design than representing dynamic child growth and development. Nevertheless, the detection
performance and risk scores for both methods could only be compared when considering data
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found within child development strata. Fortunately, the further advantage of the GAM is its ability
to model childhood as a continuous period using age without restrictive strata. This increases
the sharing of information for identifying adverse event risk during childhood which may cross
development stages and affect specific periods during childhood. This approach to share information
becomes less powerful as the noise-to-signal content increases.
2.4 Conclusion
In this study, we evaluated ADE risk detection methods to identify dynamic drug event reporting
within observational data. By simulating drug event reporting and augmenting simulated rates
into existing observational data, we can make comparisons between methods to detect dynamic
drug event reporting patterns. We found GAMs result in more robust scores, overall improved
performance to detect dynamics, and improved ability to detect simulated and real-world pediatric
drug-events compared to the state-of-the-art in pediatric drug safety studies. This study lays the
foundation to detect and evaluate pediatric adverse drug events for ontogenic-mediated mechanisms.
2.5 Methods
2.5.1 ADE data source
We retrieved drug event reports from the Food and Drug Administration’s openFDA[146]
download page, utilizing an API key with extended permissions, containing the FAERS data.
Using custom python notebooks and scripts available in the ‘openFDA_drug_event-parsing’ github
repository (DOI: https://doi.org/10.5281/zenodo.4464544), we extracted and formatted all drug
event reports prior to the third quarter of 2019. Data fields included the safety report identifier, age
value, age code e.g. year, adverse event MedDRA concept code (preferred terms), and drug RxNorm
code (various) used in our analyses. The age value was standardized to year units for categorizing
reports into the 7 child development stages according to the Eunice Kennedy Shriver National
Institute of Child and Human Development [45]. Adverse drug event MedDRA codes were mapped
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to standard concept identifiers using concept tables[147] from the OMOP common data model. The
drug RxNorm code was similarly translated to the ATC concept identifier (ATC 5th level) in OMOP
using the concept relationship table. The occurrence of an adverse drug event is defined as any
safety report where both the adverse event and drug concepts are reported together. The pediatric
report space for any adverse drug event is all reports which have age above zero and less than or
equal to 21 years old which is the upper bound for the late adolescence child development stage.
The drug event data for a given drug-event pair composed of 339,741 safety reports with a binary
indicator for reports of the event and drug, as well as the category of NICHD child development
stage for the report’s patient.
2.5.2 Simulated ADE dynamics
The objective of this study was to evaluate detection of drug-event reporting as the reporting
rate changes across child development stages with varying dynamics and effect sizes. We assert that
reporting dynamics during childhood reflect ontogenic profiles observed on molecular, functional,
and structural levels[58][138][76]. We simulated dynamic ADE reporting by combining hyperbolic
tangent functions that produced symmetric probability distributions around a given effect size to
define the probability of event reporting at drug reports. These dynamic reporting classes represent
nonlinear trends of drug-event reports across childhood. The average drug and event reporting
across reports equaled the event reporting rate multiplied by a fold change factor resulting in the
effect size of dynamic drug event reporting. The fold change followed a negative exponential
distribution with rate parameter 0.75 resulting in a fold change distribution ranging from 1 to 10
(Figure 2.20). The simulated reporting probabilities set the Bernoulli random variable to assign the
presence (1) or absence (0) of the event being reported for each of the 339,741 safety reports. We
designed 5 different dynamic reporting rates, namely ‘uniform’ (random), ‘increase’, ‘decrease’,
‘plateau’, and ‘inverse_plateau’ (Figure 2.21).
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2.5.3 ADE data augmentation
We augmented the original drug event data from FAERS with the simulated drug event reporting
dynamics. We randomly selected 500 drug-event pairs to be the positive control set for drug-events
with putative drug event reporting dynamics. We augmented the drug event data for each pair
with the previously described dynamics that we want to detect. We then randomly selected 10,000
mutually exclusive drug-event pairs to be the negative control set which were not augmented and
represented observed reporting of drugs with events within FAERS. Differences of the average
drug event reporting between the drug-event sets was computed by comparing 10 million resamples
of each distribution. Augmenting the positive control drug-event pairs resulted in 5 sets of 500
drug-event pairs, forming (drug-event, stage, dynamic) triples. The (drug-event, stage, uniform
dynamic) triple scores were the reference distribution for comparing the average difference in scores,
after 20 resamples, with ADE risk scores from the other dynamics classes.
2.5.4 ADE detection methods
Our study evaluates population stratification versus modeling statistical methods to detect co-
occurring adverse events and drugs in observational data. The proportional reporting ratio (PRR)
stratified the pediatric population into child development stages to quantify the odds for event
reporting prevalence with a drug compared to without a drug reported. The logistic generalized
additive model (GAM) quantifies the log odds for event reporting with the drug compared to without
the drug across child development stages. The methods are applied onto the drug event data to
evaluate adverse drug event detection in the presence versus the absence of putative drug event
reporting dynamics.






where ‘a’ is the number of reports with the drug and event, ‘b’ is the number of reports without the
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drug and with the event, ‘c’ is the number of reports with the drug and without the event, and ‘d’ is
the number of reports without the drug or event of interest. These are the four parameters of the PRR
equation. For each drug-event pair, we applied the PRR to each of the 7 child development stages
resulting in 7 scores. The PRR scores were log10 transformed when conducting the Shapiro-Wilk
test for normality.
We also evaluated the logistic generalized additive model[148] (GAM):
6( (E4=C)) = B(=82ℎ3, 1H = ) (2.2)
where g is a logit link function, E(Event) is the expected value of event reporting, s is a spline
function with a penalized cubic basis, nichd is the child development stage of the report’s sub-
ject, and Drug is an indicator i.e. 0 or 1 of drug reporting. Details for GAMs can be found at
references[142][149] and we specified the model using the mgcv package in R.
Briefly, the GAM is a flexible statistical model that captures nonlinear effects of covariates onto
a response. In this paper, we model the effect of the child development stage interacting with drug
reporting on the reporting of an event where the event is the reporting of the MedDRA preferred
term and the drug is the reporting of the ATC 5th level drug concept. The s() function is a spline
function where the interaction of the child development stage (main effect) and the drug (interaction
using the ‘by’ variable) is modeled according to a set of basis functions. Each development stage
defines the knot (7 in total) in which the expectation of event reporting is quantified. In the spline
function, a penalized cubic spline basis (bs = ‘cs’) is used for fitting the basis functions where the
first and second derivative of the event expectation is zero at each knot, resulting in a smooth event
expectation across stages. To mitigate overfitting or ‘wiggliness’, we used a penalized iterative
restricted likelihood approach, called ‘fREML’, with a wiggliness penalty in the objective function.
Fitting the GAM model (using the ‘bam’ function and discrete = T) produces coefficient terms,
similar to beta coefficients in logistic regression, for each child development stage. This produces
a model with 8 parameters, one for each coefficient and intercept term (the intercept term is not
utilized in this study). For each drug-event, GAM scores are generated for each child development
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stage resulting in 7 scores. It is important to note that all GAM scores produced are finite, nonzero
values.
The scores generated by each method have different variations and uncertainty in the estimated
population value. We additionally determined the lower confidence bound in which the population-
based score would be greater than 90% of score replicates. The population score and the 90% lower
confidence bound, called ‘score’ and ‘90mse’ respectively, are the score types for each method.
2.5.5 ADE dynamic detection power analysis
We performed a power analysis to determine which of the positive control drug-event pairs could
be detected for each method and score type. The generated scores may not show a drug and event
association (score above the null statistic or another significance threshold) for a child development
stage due to the method’s different assumptions and biases when applied onto observational data. To
mitigate these issues, we determined the drug event data characteristics, namely the number of drug
reports and the effect size, for each method in which reporting dynamics could be detected at or above
t = 80% power (the power or true positive rate is the fraction of scores above a number of drug reports
and effect size out of all scores; Figure 2.22). Specifically, for the (drug-event, stage, dynamic)
triple scores in the positive control set, we determined the power to differentiate scores at high
reporting rates about a given score threshold (GAM score threshold==0; PRR score threshold==1).
The reporting rates were higher at different child development stages for each dynamics class e.g.
the ‘increase’ dynamics class had higher reporting at the ‘early_adolescence’ and ‘late_adolescence’
stages (Table S1). The scores from (drug-event, stage, dynamic) triples with a high reporting
rate were only considered for reflecting dynamic drug event reporting associations. The scores
from (drug-event, stage, dynamic) triples with a low reporting rate were not considered further
due to spurious scores generated at stages without injected signal. The drug event characteristics
were determined for both the estimated population score (‘score’) and the 90% lower bound
score (‘90mse’) that represent scores with lower and higher confidence, respectively, for the ‘true’
population score. Choosing drug-event pairs at or exceeding the characteristics for each method and
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score type at or above t = 80% power resulted in a superset of (drug-event, stage, dynamic) triples
designated as positives in a reference standard for each drug event reporting dynamics class (Table
2.3). The negative control set contained the same (drug-event, stage) doubles or 70,000 scores for
each reference standard. Excluding the drug-event scores generated by the uniform class, there were
4 reference standards of positive and negative drug-event pairs for each ADE reporting dynamics
class used for detection performance evaluation.
2.5.6 ADE dynamic detection performance
We evaluated the GAM and PRR methods to detect drug event reporting dynamics across the
child development stages. Specifically, we determined the performance in differentiating scores
from (drug-event, stage, dynamic) triples in the positive control set versus the negative control
(drug-event, stage) score doubles. The positive control set contained a superset of the 500 (drug-
event, stage, dynamic) score triples (Table 2.4). The negative control set contained the same
(drug-event, stage) doubles or 70,000 scores for each reference standard. For each of the four
reference standards, we quantified the area under the receiver operating characteristic (AUROC)
curve using the R package ROCR for each detection method and score type. Confidence intervals
for other performance metrics including the AUROC were calculated using 100 bootstraps of the
risk score distributions. Performance metrics followed the conventional definitions:
– AUROC was defined as the probability of a randomly chosen positive control score being
greater than a randomly chosen negative control score.
– Sensitivity (i.e. power and true positive rate or TPR) was defined as the fraction of positive
drug-events risks greater than a score threshold out of all positive drug-events.
– Positive predictive value (i.e. precision) was defined as the fraction of positive drug-events
risks greater than a score threshold out of drug-events predicted as positive.
– Negative predictive value was defined as the fraction of negative drug-events risks at or less
than a score threshold out of drug-events predicted as negative.
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2.5.7 Dynamics sensitivity analysis
We assessed the sensitivity of the ADE detection methods to detect drug event reporting
dynamics within child development stages. We artificially removed, at 10% decrements, random
drug reports at each child development stage separately. Removing drug reports lowers the rate of
drug reporting while maintaining the event reporting rate. Specifically, at each stage, we determined
the performance of each method and score type to detect (drug- event, stage, dynamic) score triples
compared to the same negative control (drug-event, stage) score doubles at that same reduced stage.
Sensitivity was assessed iteratively at the 10% decrements within each child development stage.
We calculated performance metrics such as the above to quantify detection of drug event reporting
dynamics for each method and score type.
2.5.8 Real-world ADE validation
We applied the ADE detection methods on observed FAERS data for drug-event pairs within the
pediatric drug- event reference standard from the Global Research in Pediatrics consortium[150]. A
machine-readable dataset can be found at the ‘GRiP_pediatric_ADE-reference_set’ github repository
(DOI: https://doi.org/10.5281/zenodo.4453379). We assigned drug-event pairs with epidemiological
or mechanistic evidence in children (Control==‘C’) as the positive class (N = 26), and the cross-
product of all drugs and events that were complementary to drug-event pairs in the reference set as
the negative class (N = 123). We calculated the AUROC using the ROCR package in R and the true
positive rate using the null statistic of each method as the prediction threshold.
2.5.9 Availability of data and materials.
The FAERS data used in this study are publically available. The datasets and code sup-




Table 2.3: The number of drug-event pairs after the dynamics power analysis. Methods and
scores had differences in drug reporting and effect size thresholds to identify drug, event pairs with
atleast 80% power to differentiate scores between high and low reporting development stages.
Table 2.4: High and low drug, event reporting at child development stages for across each
dynamics class.
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Figure 2.9: Drug event reporting for positive and negative controls. The distribution of drug-
event reporting between positive and negative control set drug-event pairs across A) dynamics
classes and B) child development stages.
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Figure 2.10: GAM and PRR drug event dynamic detection 90mse score performance. A) The
receiver operating characteristic curves showing the true positive rate versus the false positive rate
for each method by drug event reporting dynamics class. The B) area under the receiver operating
characteristic curve (AUROC), power (i.e. sensitivity or true positive rate, positive predictive value
(i.e. precision), and negative predictive value across child development stages for each dynamic
class.
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Figure 2.11: GAM and PRR drug event dynamic detection 90mse score performance for each
child development stage. The A) area under the reciever operating characteristic (AUROC) curve,
the B) True positive rate (i.e. power or sensitivity), the C) Positive predictive value (i.e. precision),
and the D) Negative preedictive value within each dynamics class.
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Figure 2.12: GAM and PRR drug event dynamic detection 90mse score performance at low
drug reporting. The area under the receiver operator characteristic (AUROC) curve, the True
positive rate (i.e. power or sensitivity), the positive predictive value (i.e. precision), and the negative
predictive value for with a given amount of drug event reports.
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Figure 2.13: Drug and event reporting as drug reports are removed at child development
stages. The average number of drug, event, and drug event reports are shown at each child
development stage as drug reporting is reduced by 10% at each child development stage.
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Figure 2.14: GAM and PRR detection scores across childhood as drug reports are removed.
The average ADE risk scores are shown at each child development stage as drug reporting is reduced
by 10% at each child development stage.
Figure 2.15: GAM and PRR drug event dynamic detection 90mse score performance as drug
reports become more rare. The drug reporting for drug-event pairs was reduced at 10% decrements
only within a specific child development stage. For example, 0% drug reporting reduction indicates
no reduction in drug reporting and 100% drug reporting reduction indicates all drug reports were
removed. The area under the reciever operating characteristic (AUROC) curve, the power (i.e. true
positive rate or sensitivity), the positive predictive value (i.e. precision), and the negative predictive
value as drug reports become rare at child development stages.
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Figure 2.16: GAM and PRR score comparison for real-world pediatric drug-events. Applica-
tion of each ADE detection method on drug-event pairs from the clinically-validated GRiP pediatric
reference set. The population score and 90% confidence interval are shown for each detection
method. Only drug-event pairs with epidemiological or mechanistic evidence in children are shown.
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Figure 2.17: GAM and PRR drug event real-world drug-event detection performance. A) The
area under the receiver operating characteristic curve (AUROC) for detecting risk in real-world
pediatric drug-event pairs. B) The true positive rate (TPR) for detecting risk in real-world pediatric
drug-event pairs. Intervals represent the 95% confidence interval for the performance metric.
Figure 2.18: GAM and PRR detection scores on sample real-world and simulated drug event
data. We highlight two drug-event pairs from the A) simulated and B) real-world positive control
set where scores across child development stages reflect dynamic ADE risks
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Figure 2.19: GAM and PRR detection score variation as drug reports are removed at child
development stages. The mean and standard error of the risk score 90% confidence interval at 10%
decrements of drug reports available at stages.
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Figure 2.20: Distribution of fold-changes for generating drug event dynamics of varying mag-
nitudes. Distribution of fold-changes randomly assigned to drug-event pairs in the positive control
set for each dynamics class.
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Figure 2.21: Drug event reporting probability rates across child development stages. Each
dynamics class represents a drug event reporting probability trend for drug-event pairs in the
positive control set. An effect size, here 0.3, determined the magnitude of the drug event reporting
dynamic. The average drug and event reporting across reports equaled the event reporting rate
multiplied by a fold change factor resulting in the effect size of dynamic ADE reporting.
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Figure 2.22: Power graph detecting drug-event pairs with dynamics for each method and
score type. The number of drug reports and effect size determined the scores evaluated to detect an
association between the drug and event co-occurrence. The scores used were from child development
stages with a high reporting rate determined by the dynamic class.
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Chapter 3: A database of pediatric drug effects to evaluate ontogenic
mechanisms from growth and development
The work in this chapter is adapted in part from the following preprint:
Giangreco, Nicholas P. and Tatonetti, Nicholas P., A Database of Pediatric Drug Effects to
Evaluate Ontogenic Mechanisms From Child Growth and Development. Available at SSRN:
https://ssrn.com/abstract=3898786 or http://dx.doi.org/10.2139/ssrn.3898786
3.1 Introduction
Growth and maturation during child development are reflected by changes in the molecular
landscape that may alter pharmacokinetics and pharmacodynamics[110]. In particular, cytochrome
P450 enzymes, which metabolize 70-80% of drugs, exhibit dynamic activity during this time and
within the first weeks of life these enzymes can vary up to 100-fold[78]. Activating metaboliz-
ers such as monooxygenases, aldehyde dehydrogenases, and amidases exhibit dynamic changes
during infancy and early childhood[138]. During puberty, the hypothalamic-pituitary-adrenal axis
orchestrates orders of magnitude increases of sex hormones like precursor estradiol[151][92]. These
hormonal dynamics drastically reduce or accelerate the bioavailability of drugs[152] and regulate
receptor availability and downstream signaling[75][92]. Variations in metabolizing enzymes and
other pharmacogenes will modulate drug and metabolite activities and increase the risk of adverse
effects such as serotonin syndrome[115] and NSAID-induced hypersensitivity[153]. Pharmacody-
namic interactions can also lead to unexpected adverse effects, like paradoxical seizures following
benzodiazepine treatment[154] and heightened cyclosporin immunosuppression[91][155].
Despite strong evidence for molecular dynamics across child development and notable drug
safety examples, such as doxorubicin-induced cardiotoxicity[108] and methylphenidate-induced
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mental disorders[99], the role of child development in pediatric drug effects remains largely a
mystery. Preclinically, it is unclear if toxicity studies assess effects on child growth and development
and significantly influence the design of trials involving children[18]. When pediatric trials are
conducted (recently incentivized or required by regulation[23]), the studies include few patients
in specific age groups within too short of a time period to sufficiently evaluate drug effects during
child development[32]. This landscape is enabled by current drug safety legislation: drug safety
can be extrapolated from adults to children if 1) the disease is determined to be similar and 2)
the effect of the drug is similar between adults and children[51]. On the contrary, children are
not simply small adults[52][53][54] but can have distinct disease pathogenesis and trajectory[55].
Rapid growth and development during the period from birth through the teenage years complicates
drug treatment when disease manifests. The pediatric drug safety landscape requires a large-scale
approach, including the entire pediatric population, to ascertain the developmental contexts for this
diverse population.
Real-world observational data, such as from spontaneous reports and electronic health record
databases, can identify a diverse range of drug effects in large pediatric populations across different
growth and development contexts[109]. Importantly, observational studies can identify idiosyncratic
but clinically-relevant risks of medications taken throughout childhood[110]. Notwithstanding
the need to mitigate substantial bias inherent in real-world pediatric data, statistical and machine
learning approaches can address this challenge and investigate the interaction between prescribed
medications, observed side effects, and the developmental context of children. For newborns to
young adults, and for those with diseases both common and rare, real-world observational data
presents an opportunity to systematically investigate drug safety in the context of child development.
Current real-world observational data approaches in pediatric drug safety treat child development
as independent periods of time instead of a continuous trajectory throughout childhood. The
proportional reporting ratio (PRR), a disproportionality statistic of event prevalence associated with
drug exposure, is commonly used by researchers and agencies to identify adverse drug events in
the pediatric population. However, disproportionality statistics are limited to either modeling all
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children under 18 as one homologous group or to modeling risks within age groups which limits
their power and treats children as distinct and unrelated to their similarly developing peers[111].
We have previously shown that generalized additive models (GAMs) address these limitations
and generate robust and sensitive scores for modeling temporal adverse drug event risk across
childhood[112]. GAMs allow for sharing information between development stages to reveal drug
effect dynamics even when there may be scant evidence at a particular stage. Moreover, GAMs are
computationally efficient enough to apply in a high throughput manner to identify pediatric drug
safety signals and evaluate the biology that may be associated.
We developed a resource of nearly half a million adverse drug effect risks across child devel-
opment stages. We applied logistic generalized additive models (GAMs) to all observed pediatric
adverse drug events (ADEs) in the FDA’s adverse event reporting system, generating drug effect
risk estimates and dynamics across the stages of child development. Using GAMs, we mitigated
reporting bias through covariate adjustment and increased more than two-fold detection of rare
adverse events. Our ADE resource reproduced population-level physiological growth and develop-
ment, and identified 19,438 significant as well as known, pediatric-specific adverse drug events. Our
results identified known pediatric drug effects such as montelukast-induced psychiatric disorders,
including enriched risk (Odds Ratio 8.77 [2.51, 46.94]) within the second year of life. A data-driven
time-series clustering approach resulted in up to 95.2% precision and 97.8% sensitivity for cate-
gorizing risk dynamics across development stages for all ADEs including known but previously
developmentally-unknown pediatric drug effects. Furthermore, we evaluated and found evidence
for observed drug risks associated with expression of cytochrome P450 enzymes across child devel-
opment stages. We provide a resource for the pediatric drug safety community to further evaluate
clinical and molecular hypotheses for observed ADE risks in the context of child development.
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Table 3.1: Adverse drug events across child development stages in Pediatric FAERS. The
number and percent of reports with the subject or drug characteristics. The drug class of the reported
drug is in descending order.
3.2 Results
3.2.1 Pediatric FAERS adverse drug event reporting
There were 264,453 pediatric reports in FAERS ranging from term neonates through late
adolescents in the Pediatric FAERS dataset (Table 3.1). There were 460,837 unique drug-event
(ADE) pairs reported over three decades. Majority of reports listed Female sex (52.9%). The
most frequently reported drugs were from nervous system (35.3%), antineoplastic (26.8%), and
alimentary tract and metabolic (13.5%) pharmacological classes. More than two drugs were reported
for any given report (2.28 on average) and 95% of reports listed up to 8 drugs.
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3.2.2 Our machine learning approach mitigates ADE confounding and reporting bias
In Pediatric FAERS, we observed 94% of ADEs were reported only up to 10 times in total
(Figure 3.8A) and reporting factors such as stage, sex, reporting date, type of reporter, and class of
drugs varied across childhood (Figure 3.8B-F).
We evaluated GAM likelihood and generalizability by accounting for different factors or
reporting characteristics for drug-events (see Methods). Compared to a base model, without
covariates, accounting for sex across childhood resulted in a better model fit, specifically, a 2.1%
and 16.9% increased model likelihood and generalizability, respectively (Figure 3.1A). Alternatively,
accounting for the report date and type of reporter showed a 3.1% and 22.9% increased model
likelihood and generalizability, respectively. The likelihood of the GAMs were stable in rank when
considering different numbers of drug-event reports (Figure 3.1B). We found that separating the
number of drugs taken (‘NdrugsS’) from their drug class (‘ATCbin’) slightly improved model
likelihood (7.56% vs. 6.41% percent increase) and drug-event probability (86.3% vs. 74.3% percent
increase) compared to integrating these two factors into one composite (‘ATC’) (Figure 3.1C).
However, increasing the model complexity through separating rather than integrating factors showed
an increase in model overfitting, defined as the training from testing AUROC difference, from
-0.0062 to -0.017 (73% increase) while resulting in similar testing performance (Figure 3.1D,E).
Overfitting was also exacerbated when increasing the number of drug classes (‘ATC3’). From
these model comparisons, accounting for sex, report date, reporter, and the number of drugs within
pharmacological classes produced the most improved model likelihood, generalization performance,
and drug-event probability in a more modest time frame (Figure 3.1F).
3.2.3 A resource of child development-specific ADEs
We generated 460,837 drug-event risk estimates across childhood for 10,770 and 1,088 unique
adverse events and drug exposures, respectively. In comparison to the commonly used proportional
reporting ratio (PRR), the GAMs estimated risk by sharing information across all stages (Figure
3.2A) that generated smooth risk relationships (Figure 3.2B). We then summarized the drug-event
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Figure 3.1: Generalized additive models (GAMs) generate robust and generalizable evidence
for adverse drug events across childhood. A) The average Akaike’s Information Criterion (AIC)
versus average time, in seconds, across drug-event GAMs, per model type. B) The AIC distribution
of drug-event GAMs, per model type, between low to max reporting in drug-event sample. C) The
drug-event probability average fold change from the ‘Base’ model. The control probabilities or
drug-nonevent probabilities are shown in small squares for comparison. D) The average training
versus testing area under the receiver operating characteristic (AUROC) curve for each model type.
E) The average difference of testing from training performance or overfitting for each model type.
F) The average testing AUROC versus the average time, in seconds, to fit the training data per
model type.
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GAM risk distribution of drug-events across child development stages (Figure 3.2C). The model
identified 152,919 or 33.2% drug-events that generated at least one nominally significant risk (GAM
90% lower bound beta coefficient>0) across child development stages (Figure 3.2D). To mitigate
spurious associations, we further defined drug-event significance by comparing risk scores to a null
risk from random drug and event associations (see Methods). This narrowed our findings to 19,438
or 4.2% of drug-events passing the 99th percentile null risk threshold at each stage. The percent
of risks exceeding both nominal and null model significance thresholds were higher for earlier
child development stages (Figure 3.2E). We defined significant drug-events where at least one risk
passed nominal and null model significance thresholds (Figure 3.2F). We found significance by the
null model detected two times more drug risks for pediatric adverse events compared to nominal
significance (odds ratio 2.00 [1.85, 2.15]).
3.2.4 Drug-event GAMs identify known pediatric drug effects
We evaluated drug-event risk scores within known, or positive, drug-events compared to unasso-
ciated, or negative, drug-events. We first examined risks across childhood between 312 positive
and negative drug-events, which were not specific to the pediatric population, in the Ryan et al.
reference set. There was a 1.15-fold higher rate (relative risk 90% CI [0.72, 1.84]) of nominally
significant risks for positive compared to negative drug-events. We then examined risks across
childhood for 187 positive and negative drug-events, which were specific to the pediatric population,
curated by the Global Research in Pediatrics (GRiP) consortium. There was a 1.9-fold higher rate
(relative risk 90% CI [1.08, 3.38]) of nominally significant risks at child development stages for
positive compared to negative drug-events. We determined drug-event risk at stages, which were
unspecified previously, and found 22 (29.3%) drug-events contained nominally significant risk
scores and displayed dynamic drug-event risk across childhood (Figure 3.3).
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Figure 3.2: Drug-event GAMs estimate dynamic risks that share information across stages to
identify pediatric adverse drug events. A) The spearman correlation between drug-event risks at
child development stages from a random set of 2,000 drug-events, compared between our drug-event
GAM and the popular proportional reporting ratio. B) The normalized risk scores across child
development stages (normalized between [0,1] for each drug-event) from a random set of 2,000
drug-events, compared between our drug-event GAM and the popular proportional reporting ratio.
C) The percent of nominally significant drug-event risks (90% lower bound above 0 or the null
association) across child development stages for the drug-event GAMs. Error bars represent the
95% confidence interval for percentages calculated across 100 bootstraps of drug-events from
Pediatric FAERS. The dashed redline indicates the null association between an adverse event and
drug exposure across child development stages. D) The percent of nominally significant drug-event
risks (90% lower bound above 0 or the null association) across child development stages. E) The
percent of significant drug-event risks by the null model, out of all nominally significant drug-event
risks, across child development stages. F) The percent of significant drug-events by the null model
out of all drug-events in Pediatric FAERS.
Figure 3.3: Known pediatric drug effects show dynamic risk across child development stages.
Adverse event risk across child development stages for drug-events in the GRiP drug-event reference
set with either epidemiological or mechanistic evidence in children.
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3.2.5 Drug effects show dynamic risks by effect etiologies and drug mechanisms
We evaluated the enrichment of 1,518 medication and drug classes showing significant risks
for 8,675 MedDRA adverse events and disorders at child development stages (Figure 3.4A). We
found 282 or 0.13% of drug effects were enriched (FDR<0.05) for significant drug-events at child
development stages (Figure 3.4B). Adverse events and systemic disorders were found for both
medications and drug classes (Figure 3.4C). Of note, we identified 32 medications significantly
associated within systemic disorders (MedDRA system organ class) at child development stages
(Figure 3.4D and Table 3.2).
Figure 3.9 shows the percentage of significant drug events and their odds enrichment within each
development stage for a drug effect etiology. Younger children were associated with (odds ratio 3.19
[2.83, 3.58]) experiencing congenital disorders, as expected, where about 60% of congenital-related
drug-events were significant during the first month of life compared to other development stages.
Infants were at a greater risk (odds ratio 1.45 [1.20, 1.74]) of experiencing drug effects related
to surgeries and medical procedures. We found that nervous system disorders (odds ratio 1.16
[1.06, 1.27]) and eye disorders (odds ratio 1.25 [1.09, 1.43]) became significant risks just after the
second year of life. Endocrine disorders became significant drug effect risks (odds ratio range 1.36 -
1.58) during the stages of early childhood through early adolescence which parallels the biological
processes of puberty. Only during late adolescence were gastrointestinal disorders significant drug
effects (odds ratio 1.24 [1.10, 1.40]).
Figure 3.10 shows the percentage of significant drug events and their odds enrichment within
each development stage dependent on drug pharmacological class. Younger children were at
significant risk for drug effects from cardiovascular drugs (odds ratio 1.29 [1.16, 1.43]), mirroring
the significant risk for cardiac disorder effects (odds ratio 1.57 [1.39, 1.79]). Significant drug effect
risk from antineoplastic agents were significantly enriched in each development stage after the first
month of life (odds ratio range 1.12 – 1.23). Moreover, mirroring hormonal fluctuations that occur
during puberty, we found significant enrichment of drug risks from those affecting the genito-urinary
system and sex hormones (odds ratios range 1.28-1.38).
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Figure 3.4: Drug risks and adverse effects are associated to child development stages. Volcano
plot of the enrichment for drug-events among ATC and MedDRA classes within child development
stages. B) The number of significant enrichments at each stage (false discovery rate of 0.05) for
significant drug-events. C) The number of significant enrichments by the ATC and MedDRA
class. D) The 95% lower-bounded odds for disorders by medications with at least one significant
enrichment across child development stages. The presence of the line indicates significant drug-
events were present at that stage, and none were significant otherwise. The red dashed line indicates
the null enrichment threshold. Abbreviations: ATC: Anatomical Therapeutic Class; ATC1-5:
ATC 1st level – 5th level; SOC: System Organ Class, HLGT: Higher-Level Group Term, HLT:
Higher-Level Term.
3.2.6 ADEs had dynamic risk patterns across child development
We found drug-event GAM risk followed distinct patterns across child development stages.
However, while most risk patterns were found to be directly increasing (65%) or decreasing (28.6%),
there were 28,892 (6.4%) drug-events that fell outside these trends and remain unassigned.
We performed a data-driven clustering strategy to assign patterns for drug-events in Pediatric
FAERS. We evaluated our clustering strategy to categorize injected ‘canonical’ drug-event risk
patterns, including increase, decrease, and plateau patterns, and be both sensitive and precise
towards cluster assignments (see Methods). We found that clustering algorithms, using different
combinations of distance and centroid parameters, assigned canonical patterns to clusters with up
to 95.2% precision (cluster purity) and 97.8% sensitivity (dynamics localization; Figure 3.5A).
Increasing the number of identified clusters, even with reduced sensitivity, increased the precision
for canonical dynamics (Figure 3.5B). Moreover, treating the drug-event risks as time-series or
shapes that share information across childhood resulted in overall higher clustering sensitivity and
precision (Figure 3.5C).
We compared all pairwise drug-events in Pediatric FAERS using shaped-based distance and
partitional clustering, and found the dynamics clustered into four visually distinct risk dynamics
across childhood (Figure 3.5D). While 137,008 (65.25%) drug-events in Pediatric FAERS were
assigned to the increase dynamic cluster, only 5,397 (1.79%) were significant by the null model. In
contrast, 20,127 (4.37%) drug-events in Pediatric FAERS were assigned to the plateau dynamic
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cluster and 5,885 (29.23%) of those were significant by the null model (Figure 3.5E).
We visualized the cluster assignments per the 32 drug risks for systemic disorders enriched
within child development stages. We identified dynamic risk patterns of known drug risks, such as
montelukast-induced psychiatric disorders (Figure 3.5F). There were drugs that posed only one risk
dynamic, such as quinapril exposure and gastrointestinal disorders, and drugs that posed multiple
risk dynamics for specific sub-etiologies, such as valproic acid and congenital disorders (Figure
3.11).
3.2.7 Cytochrome P450 expression dynamics were predictive of drug effect risks across child
development stages
We took a systems biology approach to evaluate our real-world observations for putative
biological mechanisms during growth and development. For example, dynamics of cytochrome
P450 enzymes expression across child development stages may alter systemic effects of drugs we
observe in Pediatric FAERS (Figure 3.6A). We found that grouping significant drug-events by the
CYP metabolizing enzyme of the drug showed enrichment (fisher exact test FDR<0.05) within child
development stages (Figure 3.6B). We then hypothesized the expression of CYP enzymes across
child development stages is associated with observed dynamics of systemic risks by drug substrates.
We first constructed a dataset of gene expression across childhood (Table 3.3 and Figure
3.12A,B) where previously identified age-associated genes by Stevens et al. were corroborated
in our dataset following our re-normalization and adjustment procedure (Figure 3.12C and see
Methods). Genome-wide expression did not significantly change on average between infancy
through early adolescence stages (t-test FDR>0.05). We identified 22 CYP genes comprising
50 probes, with concordant probe expression within genes, that showed dynamics across child
development stages.
We evaluated shared dynamic information between adverse drug event risks and CYP enzyme
expression across child development stages. Specifically, we compared the mutual information
between CYP gene expression and drug risks by CYP substrates compared to non-substrates,
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Figure 3.5: Time-series based clustering categorizes drug risks into dynamic patterns across
child development. A) Clustering metrics dynamics localization versus cluster purity scores across
clustering models for (Number of clusters, centroid, distance) triplet hyperparameter sets. B) Cluster
metric scores and their 95% confidence interval versus the number of clusters to fit in the clustering
model. C) Cluster metric scores and their 95% CI versus the drug-event distance used to fit in
the clustering model. See Methods for details on the clustering strategy and metrics. D) Cluster
assignments assigned to putative risk dynamics categories after fitting top cluster model with all
drug-events in pediatric FAERS. The GAM coefficients were normalized between [0,1] producing
scores across child development stages for each drug-event. E) Percent of drug-events assigned
from the top cluster model that were significant by the null model. F) Montelukast-psychiatric
disorder drug-events assigned risk dynamics clusters.
accounting for risk estimate variation, across child development stages. Out of 780 significant drug-
events present on drug product labels, there were 429 drug-events where the drugs were substrates
of the 22 CYP enzymes. We found dynamic expression of CYP2C18 (t-test p-value<5.57E-23) and
CYP27B1 (p-value<1.69E-31) were more informative of drug risk dynamics by substrates compared
to non-substrates across all side effects. However, we found enzyme expression significantly
associated (t-test FDR<0.05) with drug substrate risks across multiple systemic disorders (Figure
3.6C). Specifically, we found systemic risks by drug substrates for 16 CYP enzymes contained
significant shared information across child development stages (Figure 3.6D,E).
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Figure 3.6: Drug risks from real-world observations associate with gene expression dynamics
across childhood. A) Putative metabolic models of development-dependent risk. Adverse drug
reactions (ADRs) can be influenced by dynamic metabolic processes during growth and development.
In Model A, the risk of an ADR stems from increased concentration of the drug. The decreased
metabolism, such as by the enzyme in green, increases the bioavailability of the drug resulting
in the observed ADR. In this case, drug risks are inversely proportional to expression dynamics
of this enzyme across child development stages. In Model B, the risk of an ADR stems from
the aberrant modification of the drug such as by the enzyme in green. The concentration of the
metabolite results in an observed ADR. Drug risks are directly proportional to expression dynamics
of this enzyme across child development stages. B) Enrichment of significant drug-events at child
development stages out of all drug-events with cytochrome P450-metabolized drugs. The red dashed
line indicates the null enrichment threshold, and the error bars are the 95% confidence intervals
of the odds ratio. Shown are CYP enzymes where at least one stage was significantly enriched
for CYP-metabolized drug risks across child development stages. C) Volcano plots of the average
mutual information (MI) for drug systemic risks by CYP substrates versus the -log10 t-test false
discovery rate (FDR) between substrate and non-substrate mutual information. A dashed red line
for FDR=0.05 is shown. D) The average drug substrate risk for systemic risks for each CYP enzyme
sharing significant information (t-test FDR<0.01) within systemic disorders. E) The residual probe
expression across child development stages for the CYP enzymes in B).
3.3 Discussion
3.3.1 Study overview
We systematically generated 460,837 observed adverse drug event risk estimates across child
development stages. Unlike disproportionality measures that quantify risk within age groups, our
approach using generalized additive models (GAMs) both mitigated bias and shared information to
estimate risk across stages. We assessed the impact of different factor combinations and specified
GAMs that produced robust and generalizable adverse risk estimates. This approach, for the first
time, systematically identified adverse drug event risk dynamics across childhood in all stages of
child development.
3.3.2 Biologically-inspired modeling using drug-event GAMs
GAMs enable estimating dynamic risks by sharing information across childhood. GAMs are
common in evaluating environmental and ecological characteristics over space and time, such as
black smoke particulate exposures across the UK over four decades[156] and artificial light density
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on bird stopover in different habitats during autumn migration[157]. The aim of pharmacovigilance
activities, on the other hand, has been to detect signal for potential and rare adverse effects from
marketed medicinal products[158]. Disproportionality methods have served this monitoring purpose,
and for the pediatric population the common practice of stratifying data into age groups was shown
to uncover signal that would otherwise go unnoticed[111]. Alternatively, our approach goes beyond
monitoring and towards evaluating drug effects over time as children grow and develop on molecular,
physiological, and structural levels. We flip-the-script in pediatric drug safety by developing and
applying a strategy informed by pediatric developmental biology.
3.3.3 Drug-event GAMs were more robust and predictive of pediatric adverse events
Our models quantify relationships for every drug and adverse event co-reported across pediatric
age groups as opposed to isolated pediatric groups. In this way, we were able to extract dynamic
risk information across child development stages instead of concatenating isolated risks. Despite
including a quarter of a million reports with very few events co-reported with a drug in our models,
we extracted useful information based on 1) increased model fit to the data when considering
important factors that contribute to adverse drug events[8][159] and 2) increased generalizability for
a hold-out test set with modest overfitting. This robust, systematic approach generated hypotheses
of pediatric drug effects including rare adverse drug events.
3.3.4 Drug-event GAMs identify known pediatric drug effects
We identified putative risk dynamics for known pediatric drug effects. We generated evidence
of the risk for all pediatric-specific adverse drug events curated by the Global Research in Pediatrics
(GRiP) consortium[150][160]. We now provide a temporal map of the risk for these pediatric
drug-events across child development stages that was unspecified previously. For known culprits
such as montelukast, our approach identified significant risk during mid-childhood (Figure 3.3)
corresponding to studies from the Swedish ADR database[161] and the World Health Organization’s
Vigibase[162][163]. Moreover, our unsupervised clustering approach further evaluates the dynamics
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of these and thousands of drug risks that were previously unknown. We categorize dynamics of
drug-events that visually correspond to their temporal trend across child development stages, as
expected. Importantly, our systematic approach generates evidence for classes of medications
resulting in seemingly distinct but temporally-related side effects.
3.3.5 Drug-event GAMs cluster within robust risk dynamic patterns across child development
We investigated patterns of half a million drug risks across all drugs and adverse events in
the population. We optimized our clustering procedure to accurately and precisely cluster known
(through simulation) drug risk dynamics. Our procedure rediscovered the canonical (through our
simulation study[112]) cluster ‘inverse plateau’ that we intentionally left out, which signifies its
ability to generate clusters of canonical trends over time. Cluster assignments can now be utilized
to test hypotheses for enriched drug risk dynamics by common therapy, disease, and type of side
effect. This can only be done by having large amounts of drug risks available. Our novel data
mining methodology is the first approach to evaluate when during childhood side effect risk may
be occurring for a particular drug therapy or drug class. From thousands of drug effects, we can
investigate effects arising from medications with shared pharmacology.
3.3.6 Drug-event GAMs facilitate evaluating ontogenic-mediated pediatric drug effects
Our database enables for the first time the ability to investigate pediatric, ontogenic biology from
observational data. For example, the cytochrome P450 enzymes, which metabolize about 70-80%
of drugs on the market, exhibit dynamic changes in activity across child development that result
in altered drug actions and effects[115][164]. Notably, these enzymes show characteristic activity
patterns where it is generally thought CYP enzymes surge in activity during the first few years of life
and then gradually decline to mature levels[165]. From our approach, we showed drug risks within
stages throughout childhood are enriched when metabolized by CYP enzymes. We curated a gene
expression dataset to evaluate a biological underpinning or shared information between our observed
risks and the expression of drug enzymes across child development stages. We found evidence
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for ergocalciferol, also known as vitamin D2, resulting in risks for Polyuria, Hypercalciuria, and
Hypervitaminosis D corresponding with CYP27B1 metabolism, where ergocalciferol treatment was
previously shown to result in abnormally high calcium levels in younger pediatric patients[166].
We also identified evidence of drug risk dynamics associated with CYP2C18 expression, where the
ontogeny of this gene isoform is not known but drug binding was found to be different compared
to other CYP2C gene family isoforms[167]. There were four drug-event substrates different from
other CYP2C family substrates, comprising the three drugs cyclophosphamide, ifosfamide, and
omeprazole. The alkylating agents ifosfamide and its parent compound cyclophosphamide are
known to share a toxicity profile of myelosuppression and urotoxicity[168], but our data suggest
and corroborate the long term effect of severe cellular damage and possible infertility in pediatric
cancer-survivors[169]. Moreover, our observational analysis corroborates omeprazole risk for the
benign adverse effect of enlarged breast tissue in neonates that stems from increased oestrogen
production[170] (Figure 3.7). Our resource allowed for generating clinically-relevant molecular and
developmental hypotheses found through a systematic data mining approach.
3.3.7 Pediatric drug effect resource
We made available, for the first time, a database of half a million pediatric drug effects across
growth and development stages. We have shown how a massive data mining effort captures known
pediatric drug effects and reproduces system-wide development patterns. We included standardized
drug and adverse event vocabulary information as well as derived clustering and stage enrichment
data to further investigate both clinical and molecular pediatric ADE hypotheses. Importantly, we
include a summary of the covariates within our significant drug-event GAMs to illuminate the
data-context, as well as promote equitable treatment of our predictions, for which we generated
these hypotheses. Our resource is novel in both its accessibility to the clinical community but also
to researchers for evaluating mechanistic hypotheses such as metabolic associations on observed
drug risk dynamics as shown here for substrates of CYP enzymes. We include additional data
for evaluating shared information between drug risks and their targets, carriers, transporters, and
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Figure 3.7: Adverse event risk dynamics by CYP2C18 drug substrates associate with the
enzyme’s expression dynamics. We found CYP2C18 as one of the only two CYP enzymes
significantly associated with adverse risks of their substrates. The drugs in each drug-event are
metabolized only by CYP218 and no other CYP2C family gene. Each drug-event is reported in
each facet with different colors. Bars are in red, blue, and green to indicate the number of drug,
event, and drug-event reporting, respectively, in Pediatric FAERS. Related to Figure 6.
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enzymes. We make available our findings to the research community to accelerate pediatric drug
safety research.
3.3.8 Limitations
This study has some limitations. First, the observations of drug reporting over time in FAERS
contain biases and confounding factors that may impact our risk estimates. While we mitigate
potential biases by including confounding factors in our GAMs, we acknowledge that our models
may still contain these biases. For example, we did not take into account drug dosage, which is a
known factor in drug toxicity. This treatment characteristic was rarely present in our data and so we
could not adequately consider this factor in our drug-event GAMs. Though our model evaluation
strategy was not exhaustive in performance metrics and model factors, we showed reduced bias
and increased signal when accounting for known adverse drug event risk factors. We represented
child growth and development through pre-defined stages with age ranges defined by NICHD
which were intended to standardize consistent age groups for randomized clinical trials. These
stages, however, remain temporally-related and were evaluated by multiple stakeholders such as the
American Academy of Pediatrics and the Centers for Disease Control and Prevention. Our approach
generated nonzero risk at stages for drug-events with no reporting. While it is difficult to interpret
nonzero risk estimates at stages with no occurrence of a report, the sharing of information between
stages including report and drug characteristics promoted risk estimation. Nevertheless, nonzero risk
estimation from no explicit reporting at a stage may provide an opportunity to alleviate the burden of
underreporting of medication side effects. While we performed a stringent strategy to generate CYP
expression that corresponded with the original Stevens et al. findings, our latent representation was
not validated against another data source. Nonetheless, this triangulation procedure augments real-
world evidence to pinpoint putative metabolic mechanisms for our observed drug risks. Our resource
not only lends itself to assess when during childhood risks may occur, but also toxicities arising





We created “Pediatric FAERS” as a subset of the existing FAERS database limited to those
patients aged 21 or younger and specifying either Male or Female sex. We retrieved drug event
reports from the Food and Drug Administration’s openFDA[146] download page, utilizing an API
key with extended permissions, containing the FAERS data. The data is comprised of safety reports
listing at least one drug and at least one adverse event. Using custom python notebooks and scripts
available in the ‘openFDA_drug_event-parsing’ github repository (DOI: 10.5281/zenodo.4464544),
we extracted and formatted all drug event reports prior to the third quarter of 2019. Data fields
included the safety report identifier, age value, age code e.g. year, adverse event the Medical
Dictionary of Regulatory Activities concept code (preferred terms), and drug RxNorm code (various)
used in our analyses. The age value was standardized to year units for categorizing reports into the
7 child development stages according to the Eunice Kennedy Shriver National Institute of Child and
Human Development[145]. Adverse drug event MedDRA codes were mapped to standard concept
identifiers using concept tables[147] from the OMOP common data model. The drug RxNorm code
was similarly translated to the equivalent Anatomical Therapeutic Chemical (ATC) Classification
concept identifier (ATC 5th level) using the concept relationship table. The occurrence of an
adverse drug event is defined as any safety report where both the adverse event and drug concepts
are reported together. The pediatric report space for any adverse drug event is all reports which
have age above zero and less than or equal to 21 years old which is the upper bound for the late
adolescence child development stage. All pediatric reports reported either Female or Male sex,
contained the type of reporter (Physician, Consumer, lawyer, or other health professional), and the
date of the report. Additionally, we joined the higher-level ATC class for drugs from the drugbank
database[171], with code to generate the database on GitHub (DOI: 10.5281/zenodo.4464604).
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3.4.2 ADE detection models
We compared two different models for detecting adverse drug events from spontaneous reports.
First, we applied the logistic generalized additive model[148] (GAM) to all unique drug-event pairs
in Pediatric FAERS. The drug-event GAM was used to quantify adverse event risk due to drug
exposure versus no exposure across child development stages. We refer to the ‘base’ GAM formula
as:
6( (E4=C)) = B(=82ℎ3, 1H = AD6) (3.1)
where 6 is a logit link function,  (E4=C) is the expected value of event reporting, B is a
spline function with a penalized cubic basis, nichd is the child development stage of the report’s
subject, and Drug is an indicator i.e. 0 or 1 of drug reporting. Details for GAMs can be found at
references[149][142] and we specified the model using the mgcv package in R. Furthermore, we
evaluated different model types or GAMs including different combinations of covariates: the smooth
interaction effect between the report’s subject being in a child development stage and reporting
female or male sex (‘Sex’), the date of first reporting the drug-event (‘Date’), the type of reporter
for the drug-event (‘Reporter’), the number of drugs in ATC level 1 pharmacological drug classes
for the report’s subject (‘ATC’), the number of drugs in ATC level 2 therapeutic drug classes for the
report’s subject (‘ATC3’), the exposure of a drug within ATC level 1 pharmacological drug classes
for the report’s subject (‘ATCbin’), the exposure of a drug within ATC level 2 therapeutic drug
classes for the report’s subject (‘ATC3bin’), and a smooth effect for the number of drugs taken by
the report’s subject (‘NdrugsS’).
Briefly, the GAM is a flexible statistical model that captures nonlinear effects of covariates
onto a response. In this paper, we model the effect by the child development stage interacting
with drug reporting on the reporting of an event where the event is the reporting of the MedDRA
preferred term and the drug is the reporting of the ATC 5th level drug concept. The B() function
is a spline function where the interaction of the child development stage (main effect) and the
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drug (interaction using the ‘by’ variable) is modeled according to a set of basis functions. Each
development stage defines the knot (7 in total) in which the expectation of event reporting is
quantified. In the spline function, a penalized cubic spline basis (bs=’cs’) is used for fitting the basis
functions where the first and second derivative of the event expectation is zero at each knot, resulting
in a smooth event expectation across stages. To mitigate overfitting or ‘wiggliness’, we used a
penalized iterative restricted likelihood approach, called ‘fREML’, with a wiggliness penalty in the
objective function. Fitting the GAM model (using the ‘bam’ function and discrete=T) produces
coefficient terms, similar to beta coefficients in logistic regression, for each child development stage
for the association of the adverse event being reported in interaction with reporting the drug. We
generated GAM scores for each child development stage resulting in 7 scores for each drug-event
pair. It is important to note that all GAM scores produced were finite, nonzero values.
In addition, we made a comparison to the Proportional Reporting Ratio (PRR):
(0/(0 + 2))/(1/(1 + 3)) (3.2)
where ‘a’ is the number of reports with the drug and event, ‘b’ is the number of reports without
the drug and with the event, ‘c’ is the number of reports with the drug and without the event, and
‘d’ is the number of reports without the drug or event of interest. The resulting score is the event
reporting prevalence with the drug compared to without the drug. We generated PRR scores for
each child development stage resulting in 7 scores for each drug-event pair. We determined the
lower confidence bound in which the population-based score would be greater than 90% of score
replicates. A risk was nominally or statistically significant if the score had a 90% lower bound
above the null association (null association: GAM==0, PRR==1). The drug-events from Pediatric
FAERS were nominally significant if at least one risk, the risk coefficient’s 90% lower bound, was
above the null association. The GAM coefficients and PRR scores were normalized between [0,1]
producing scores across childhood for each drug-event to generate normalized scores.
We derived a null GAM to evaluate significance of drug-event risk compared to random drug and
event reporting. We randomized drugs and events for reports, maintaining the report characteristics,
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and then recalculated the drug-event GAMs for 10,000 randomly selected drug and event pairs.
The null GAM risk coefficients for each stage resulted in a null distribution of risks for randomly-
associated drugs and events. A risk was significant by the null model if the score had a 90% lower
bound above the 99% percentile of the null GAM coefficient distribution at a stage. The drug-events
from Pediatric FAERS were significant by the null model if at least one risk, the risk coefficient’s
90% lower bound, was above the 99% of the null distribution for that stage. This ensured that at
least one risk at a child development stage was nominally significant as well.
Unless otherwise specified, all statistics in brackets are the lower and upper 90% confidence
intervals.
3.4.3 ADE detection model likelihood and performance
We evaluated the generalizability and model likelihood i.e. fit of a drug-event GAM, including
each model type, on a random sample of 2,000 drug-events from Pediatric FAERS. We quantified
model statistics using a proportion of the 2,000 drug-events that were reported 50 or more times
and an additional, complementary set of drug-events with less than 50 reports. We quantified the
fit of the drug-event GAMs using the Akaike’s Information Criterion (AIC), which is a measure
of the tradeoff between model likelihood and complexity. We quantified the generalization of
the drug-event GAMs by fitting each model on 80% of the dataset, termed the training set, and
quantifying the area under the receiver operating characteristic (AUROC) curve on both the training
set and the unseen testing set. The training and testing sets were balanced in having the same
proportion of reports with (20%) and without (80%) the adverse event. Each model type was fit on
the same training set.
3.4.4 Drug-event reference sets
Ryan et al. reference set
We downloaded the adverse event reference set developed by Ryan et al.[172] containing
manually curated positive and negative control drugs associated to four outcomes: acute liver injury,
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acute kidney injury, acute myocardial infarction, and upper gastrointestinal bleeding. We mapped
RxNorm concepts to ATC 5th level. There were 1078, 59, 284, and 928 unique adverse drug events,
both positive and negative controls, for each outcome, respectively. We found 312, comprising only
three outcomes, out of 2,349 total drug-event pairs (13%) within Pediatric FAERS. There were 74
negative and 238 positive drug-event pairs.
GRiP pediatric reference set
We extracted the drug-event pairs observed in Pediatric FAERS listed within the pediatric
drug-event reference standard from the Global Research in Pediatrics consortium[150]. A machine-
readable dataset can be found at the ‘GRiP_pediatric_ADE-reference_set’ github repository (DOI:
10.5281/zenodo.4453379). We assigned drug-event pairs with epidemiological or mechanistic
evidence in children (Control==’C’ and Control==’B’) as the positive class (N=179 and 75 in
Pediatric FAERS), and the cross-product of all drugs and events that were complementary to drug-
event pairs in the reference set as the negative class (N=397 and 112 in Pediatric FAERS). In total,
we evaluated 187 positive and negative drug-events observed in Pediatric FAERS.
3.4.5 Pediatric adverse events
We downloaded and joined standard concepts to the pediatric adverse event term list from the
MedDRA website (https://www.meddra.org/paediatric-and-gender-adverse-event-term-lists). This
term list is no longer supported but we provide a machine-readable version in our resource.
3.4.6 ADE clustering
We identified clusters of risk patterns across development stages for all drug-events in Pediatric
FAERS. We considered ADE risk patterns as time series, representing temporal drug-event risk
across child development stages. The temporal risk scores are the normalized, between 0 and 1,
GAM scores of the interaction between child development stage and drug exposure. We used
the R package dtwclust[173] to compare different distance and centroid methods due to ease of
implementation and optimization of computationally expensive methods. We performed an iterative
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procedure to evaluate the clustering by different combinations of distance and centroid methods.
We used a partitional clustering strategy, which minimizes the intra-cluster distance while
maximizing the inter-cluster distance by iterative greedy descent to converge to a local optima[174].
The distance methods evaluated were dynamic time warping (DTW), which is a fast implementation
to find the optimum warping path between two drug-events (‘dtw_basic’); the shape-based distance
(‘sbd’), which is a shift and scale-invariant comparison of time series based on the k-Shape
algorithm[175]; and the triangular global alignment kernel (‘gak’), which is a kernel method unlike
DTW that has been shown faster and more efficient in classification tasks[176]. The centroid
methods that evaluated cluster assignment for drug-events were the average risks between drug-
events across childhood (‘mean’); the partition-around-medoids (‘pam’), which utilizes one of the
series as the cluster centroid; DTW barycenter averaging (‘dba’), which finds the optimum average
drug-event between drug-event series in DTW space; and shape averaging (‘shape’) based on the
k-Shape algorithm, which extracts the most representative drug-event dynamic to utilize as the
centroid[175].
We fit the clustering model, with hyperparameter sets that include a distance metric, centroid
method, and number of clusters K, on a random sample of 10,000 drug-events from Pediatric
FAERS along with spiked-in ‘canonical’ dynamics patterns. We assert that reporting dynamics
during childhood reflect ontogenic profiles observed on molecular, functional, and structural
levels[138][58][76]. The canonical drug-events previously studied, including filtering for the
ranked pattern of interest, were categorized as ‘increase’ (N=237), ‘decrease’ (N=224) , or ‘plateau’
dynamics (N=106)[112]. We quantified clustering performance for each hyperparameter set using
the drug-events in each canonical dynamics’ category and their cluster assignment (see Figure 3.13
for details and illustrations of the strategy). Overall, we developed two custom metrics: 1) Cluster
purity, which is the clustering precision or the score for drug-events from a canonical dynamics
category assigned to a cluster, and 2) Dynamics localization, which is the clustering sensitivity or
the score for drug-events within a cluster from a particular canonical dynamics’ category. This
ensured the clustering performance , both the cluster purity and dynamics localization, for each
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hyperparameter set scores the homogeniety in both the assignment of dynamics and type of dynamics
within clusters. We only considered the predominant or most frequent cluster for each of the three
dynamics to compute the above metrics, allowing for comparing performance for K>3 (see Figure
3.13 for details and illustrations of the strategy).
3.4.7 ADE stage enrichment
We evaluated the enrichment of drug-events, which were significant by the null model, within
child development stages and categories of drug-events. We calculated the fisher’s exact test to
evaluate enrichment of drug-events within a specific category to also have a significant risk, by the
null model, at a specific stage.
3.4.8 Pediatric gene expression dataset
Dataset processing
We extracted expression data from GEO and EBI microarray datasets utilized by Stevens
et al.[75] to derive gene expression across child development stages (Table 3.3). We compiled
datasets’ raw image (CEL) files (affymetrix images only) and integrated annotation to the microarray
probe sets. We used the Bioconductor R package affy to load the microarray data. Samples
were preprocessed together per the same assay (hgu133a, hgu133b, and hgu133plus2) closely
aligning to the procedure in Stevens et al. Specifically, we used Robust Microchip Average
(RMA) background correction (‘rma’), quantile normalization (‘quantile’), perfect match correction
algorithm (‘pmonly’), and mean probe set summarization (‘avgdiff’). We used the R package
ROMOPOmics (DOI: 10.5281/zenodo.4463257) to extract phenotypic data from each GEO dataset
(the ‘TABM666’ dataset was downloaded from the EBI website) and convert the age of each sample
from the datasets to year units. We defined the NICHD child development stages using the age
of the samples within the stage’s age boundaries[145]. We mapped probe set IDs to uniprot IDs
and to gene symbols using the libraries of each assay’s annotation R package within Bioconductor.
We evaluated the average difference in log2 probe expression values, using 10,000 samples with
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replacement, by Students t-test between each adjacent child development stage.
Dataset validation
We performed a validation analysis to evaluate the processed gene expression data to reproduce
the significant age-associated findings published by Stevens et al[75]. Specifically, there were 690
genes comprising 927 probes with expression that was significantly associated to age. We then
performed an association analysis to evaluate significant stage-associated genes from our gene
expression dataset (we only utilized the datasets from their main analysis dataset: GSE11504,
GSE9006, and TABM666). We quantified stage-association of each probe’s expression using a
GLM where the probe value was the dependent variable and the NICHD stage, where each category
was an integer, the first six principal components (Figure 3.12B), and GEO series indicator minus the
intercept term were predictors or covariates. We computed the odds ratio using the hypergeometric
test to compare overlap of age-associated and stage-associated genes, compared to those that were
not, at different alpha significance thresholds (we required at least one probe to be significantly
stage-associated per gene). We found that the enrichment of genes in our data to be robust at
varying significance levels (Figure 3.12C). The robust enrichment provided evidence that our gene
expression dataset was capturing accurate dynamic expression patterns across childhood.
3.4.9 Pediatric cytochrome P450 gene expression dynamics evaluation
We evaluated whether drug-event risk dynamics were dependent on expression dynamics of the
drug’s substrate using our pediatric gene expression dataset. Again, we only utilized the datasets
from the Stevens et al. main analysis dataset: GSE11504, GSE9006, and TABM666.
First, to account for observed batch effects (Figure 3.12B), we performed a regression for every
probe to mitigate bias of gene expression dynamics across child development stages and all datasets.
We used the residual probe levels from a GLM where the dependent variable was the observed
values, the observations were each sample, and the covariates were the first six principal components
and the GSE series indicator. Importantly, the GLM did not include association to development
stages so that the residuals would capture the difference between observed probe values and the
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batch-predicted probe values (again, we only utilized the datasets from their main analysis dataset:
GSE11504, GSE9006, and TABM666). We used these probe residual values in our downstream
analysis.
We identified cytochrome P450 gene products using a regex expression ‘∧CYP’ on gene symbols
to extract probe-level expression data. We performed a correlation analysis between pairs of probes
within non-random CYP gene products and removed probes that showed a negative correlation
(Pearson r<0) in at least one pairwise comparison.
We manually scraped drugbank webpages to determine the mapping between drug enzymes and
uniprot IDs. We then filtered for drugs that were annotated as substrates for CYP gene products,
again using the gene symbol pattern matching to the regex expression ‘∧CYP’. We only considered
drug risks where side effects were listed on the drug’s label according to SIDER 4.0[177] (N=780).
We hypothesized expression of CYP enzymes across child development stages influence the
adverse event risks of drugs they metabolize versus do not metabolize. In other words, drugs that
are substrates for CYP enzymes generated drug-event risks with more shared information with
expression dynamics than drugs that are not substrates. We generated the two distributions by
computing the mutual information (MI), using the maigesPack R package in Bioconductor, between
the CYP probes’ residual expression, averaged across samples, and drug risks’ score for each child
development stage, if both expression and risk were present. We generated a distribution of mutual
informations from (drug-event, CYP gene probe, z score) triplets. The drug-event risk score at each
stage varied according to a randomly selected z-score from a standard normal distribution. We used
the mean (mu) and the standard error (SE) of the GAM estimates to generate a new risk score at
each child development stage:
A8B:B2>A4 = I ∗ ( + <D (3.3)
These z-score permutations generated substrate MIs and non-substrate MIs for each CYP
enzyme. The two MI distributions were compared using Student’s t-test to evaluate a greater
difference in average mutual information for substrate compared to non-substrate drug-event risks
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for their substrate’s gene expression. Also, we computed a Mann Whitney one-sided test to evaluate
whether the substrate risk comparisons were greater in rank than non-substrate risks, on average
across possible risk variations for a drug-event and CYP probe residual expression. We derived
an AUROC statistic by normalizing the Mann Whitney U statistic for the number of comparisons
between substrate (=0) and non-substrate (=1) doublets:
*'$ = */(=0 ∗ =1) (3.4)
We made these comparisons across all event disorders, detailed above, as well systemic events
of a system organ class by the same procedure.
3.5 Supplemental Material
Figure 3.8: Observed adverse drug events vary in reporting characteristics across child de-
velopment stages. A) The proportion of adverse drug events or drug-events out of all unique
drug-events with a number of reports in pediatric FAERS. B) The percent of drug-events across
child development stages by C) sex, D) drug-event reporter qualifications, E) drug class, and F)
date, spanning between 1990 and 2020, of drug-event reporting. Related to Table 3.1.
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Table 3.2: Medications pose risks for systemic disorders at child development stages. En-
richment results for the ATC 5th level drugs enriched for MedDRA SOC-level events at a child
development stage. The columns are ordered by child development stage then FDR. Related to
Figure 4. Abbreviations: ATC5: ATC 5th level; SOC: System Organ Class, HLGT: Higher-Level
Group Term.
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Figure 3.9: Drug risks vary by etiology across child development stages. A) The percent of
significant drug-events, by the null model, at child development stages out of all drug-events within
anatomical therapeutic classification (ATC) level 1 pharmacological classes. B) The enrichment of
significant drug-events by pharmacological class at child development stages. The red dashed line
indicates the null enrichment threshold. Related to Figures 2 and 4.
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Figure 3.10: Drug risks vary by drug mechanisms across child development stages. A) The
percent of significant drug-events, by the null model, at child development stages out of all drug-
events within MedDRA system organ class (SOC) etiologies. B) The enrichment of significant drug
events by SOCs at child development stages. The red dashed line indicates the null enrichment
threshold. Related to Figures 2 and 4.
Figure 3.11: Medications posing development risks have characteristic dynamics across child-
hood. Drug-events were assigned risk dynamics clusters and also grouped within MedDRA system
organ classes or systemic disorder. Related to Figures 3.4 and 3.5.
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Figure 3.12: Mitigating bias in gene expression across child development stages shows associ-
ation with previously found age-associated gene markers. A) Log2 probe-level gene expression
across child development stages. Outliers are not shown. B) Dimension reduction of microarray
expression across 576 samples and 39,558 probes. Dimensions were included in deriving stage-
association. C) Enrichment analysis, at varying alpha significance thresholds, from our final gene
expression dataset for the 690 significantly age-associated genes from the original Stevens et al.
study. All alpha levels from the range of p-values, in tenth increments, are shown. Related to Figure
6.
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Figure 3.13: Clustering performance captures purity and localization of canonical dynamic
drug-events in clusters. A) The cluster purity confusion matrix where each value is the fraction
of canonical drug-events assigned to each cluster out of all drug-events in each cluster. Example
breakdown for a hyperparameter set including the number of clusters K=3. The numbers shown
are rounded to the second significant digit. B) The dynamics localization confusion matrix where
each value is the fraction of canonical drug-events assigned to each cluster out of all drug-events in
each canonical dynamics’ category. C) The product of the maximum cluster purity and dynamics
localization score for each (cluster, canonical dynamics) pair. D) The overall cluster purity and
dynamics localization score for a hyperparameter set. The overall score is derived in a two-step
calculation from the scores in A and B): We identify the maximum cluster purity for each (cluster,
canonical dynamics) pair and then average the cluster purity across canonical dynamics categories
and the dynamics localization across clusters, respectively. This ensures the optimized score for
each hyperparameter set scores homogeniety in both the canonical dynamics cluster assignment and
the type of drug-events contained in clusters. This performance strategy is agnostic to the number
of clusters K in each hyperparameter set. Related to Figure 4.
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Table 3.3: The dataset of gene expression across childhood is made up of various datasets
across development stages and tissues. All referenced Affymetrix image data from Stevens et al.
Abbreviations: PBMCs: Peripheral blood mononuclear cells. Related to Figure 3.6.
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Chapter 4: Pediatric drug effect evaluation studies
4.1 Introduction
Pediatricians adhere to guidelines based on the best available evidence when prescribing medica-
tions to their patients. However, the evidence on medication safety can be biased due to inaccurate
extrapolation from adult studies and under-powered, development-agnostic associations from pe-
diatric clinical trials. Thus, drug safety information for children is often limited or incomplete,
which can result in severe adverse reactions. In response, we developed a data-driven approach that
generated an accessible database that estimates drug risks from all observed side effects across child
development. In this dissertation and associated publications, we showed our statistical method
is sensitive to detect even rare adverse drug events by sharing information during growth and
development.
In this chapter, we investigate clinically-relevant associations between drugs and adverse effects
using our resource. We identified adverse drug effects in children cited in the literature that were
either rarely or commonly observed in the clinic. These case studies present pediatric adverse drug
effects in clinical and biological detail for framing the objective of our computational investigation.
In all cases, we manually corresponded medications and adverse reactions to standard ATC and
MedDRA concepts, respectively. The curated drug-event set was queried within our database
for evidence of reporting and risk across child development stages. The following analyses use
the same methodologies and statistics detailed in the previous chapters. We hypothesize that,
using our resource, we can identify known pediatric adverse drug events and suggest putative
mechanistic hypotheses between drug pharmacology and biological child development. In addition
to this case series, we deployed an accessible web application, the Pediatric Drug Safety portal
(PDSportal), for retrieving and summarizing adverse drug event reporting and risk estimates across
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child development stages.
4.2 Drug-induced Serotonin Syndrome
The first clinical report of serotonin syndrome, a drug-induced disorder, originated from a
clinical trial in June 1951, where iproniazid therapy was found to be more effective in treating
pulmonary tuberculosis but was withdrawn due to severe side effects of the nervous system[178].
The clinical manifestation of serotonin syndrome comprises a triad of signs and symptoms: neuro-
muscular hyperactivity, altered mental status, and autonomic hyperactivity[179]. Notwithstanding,
patients diagnosed with serotonin syndrome may only experience some of these, and the diagnosis
can range from mild to life-threatening forms in both children and adults. During childhood,
adolescent polypharmacy is strongly associated to their diagnosis. There are also documented cases
of serotonin syndrome in younger children due to other medications such as fentanyl[180], but these
published cases are rare.
Serotonin syndrome, also known as serotonin toxicity, manifests from taking medications that
increase intrasynaptic serotonin levels[181] [182]. In 1960, Dr. John Oates and Dr. Albert Sjoerdsma
treated patients with 20-30mg of tryptophan, a metabolite of serotonin, and observed signs of
serotonin syndrome in patients where monoamine oxidase (MAO) enzyme was inhibited[181]. The
treatment methylene blue, a substance used during surgical procedures, was found to precipitate
serotonin toxicity through acting as an inhibitor of MAO[183]. From a disproportionality analysis
in the FDA’s adverse event reporting system, serotonin receptors were hypothesized as molecular
targets associated with serotonin syndrome during concomitant use of selective serotonin reuptake
inhibitors[184]. Genetic variation found in enzymes, such as the cytochrome P450 family, have
been implicated for contributing to serotonin syndrome based on patients’ entire drug regimen[185].
However, the role of receptors and other enzymes such as CYP2D6 in contributing to serotonin
syndrome or other serotonergic symptoms is unknown[186]. There is an opportunity to evaluate
real-world evidence for drug-induced serotonin syndrome across child development stages and
hypothesize putative mechanisms.
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Using our resource, we identified serotonin syndrome as a singular adverse event concept
(OMOP identifier 36718458; N=538 reports) and found the adverse event co-reported with 162
medications most frequently within adolescence but across child development stages (Figure 4.1A).
Out of these 162 drug-event associations, there were only 11 out of 162 observed drug-events that
were significant from random association (Figure 4.1B). We found that significant drug-events
were enriched (3.83 [1.51, 8.09]) at the middle childhood stage encompassing children 6 through
11 years of age. Moreover, we found that 26.4% of significant drug risks showed increased and
enriched risk after the first year of life (the toddler stage) through middle childhood (Figure 4.1C,D).
Significant drug risks were co-reported with an average of 5.3 other medications during middle
childhood, which was up to two times greater compared to other stages. Moreover, serotonin
syndrome drug-events reported higher polypharmacy, on average, compared to other significant
drug-events during middle childhood (t-test p-value<0.08). We identified only one significant drug
risk, linezolid, acting as an inhibitor of monoamine oxidase.
We evaluated the association between significant drug risks and the expression of all the drugs’
gene partners and found that the dynamic expression of ABCB1 transporter significantly associated
(FDR<1.2E-19) to the serotonin syndrome risk by its drug substrates across child development
stages (Figure 4.1E,F). The gene ABCB1 encodes for a P-glycoprotein transporter, which has
been shown to increase in expression activity across childhood in autopsied liver samples [80],
but its activity through childhood across different tissues is unknown[81][187]. Additionally, we
summarize all drug-gene linkage information available from our resource that can be leveraged
to evaluate the role of molecular enzymes, targets, and other gene products within drug-induced
serotonin syndrome (Figure 4.1G).
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Figure 4.1: Investigation of serotonin syndrome drug-events. A) The number of reports for the
drug and adverse event co-occurrence across child development stages. B) The GAM risk log odds
and the number of drug-event reports (log10 transformed) for the significant, by the null model,
drug-events. C) The odds enrichment of significant serotonin syndrome drug-events at a child
development stage. D) The breakdown of significance for serotonin syndrome drug-events assigned
within each risk dynamics category. E) The average drug substrate risk for serotonin syndrome
for each gene sharing significant information (t-test FDR<0.01). F) The residual probe expression
across child development stages for the genes in B). G) The drug-gene linkage information for
significant drug risks extracted from drugbank webpages.
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4.3 Drug-induced SCARs
Severe cutaneous adverse reactions (SCARs) to drugs are potentially life threatening side effects
that can result in acute complications such as sepsis to long-term complications such as scaring[188].
The clinical entities associated with SCARS are Stevens-Johnson syndrome (SJS), Toxic epidermal
necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS)[189]. SJS
and TEN are severe reactions that exist on a spectrum, resulting in an inflammatory response and
necrotic lesions within a few weeks of exposure as opposed to DRESS that manifests weeks later.
Drug-induced SJS/TEN are rare occurrences in both the adult and pediatric populations. From
our resource, we identified 1,124 and 771 reports of Stevens-Johnson syndrome (SJS) and Toxic
epidermal necrolysis (TEN), respectively (OMOP identifiers 36009724 and 36009754). A pooled
analysis of patients from European hospital sites identified four drug risks in children less than
15: anti-infective sulfonamides, phenobarbital, carbamazepine, and lamotrigine[190]. Moreover,
the FDA issued a black box warning on Lamictal, where lamotrigine is the active substance, for
increasing the incidence of SJS in children under the age of 16. We found SJS/TEN were co-reported
with 357 medications most frequently within early adolescence (between 12 and 18 years of age)
but across child development stages (Figure 4.2A). Out of these 357 drug-event associations, there
were only 12 (3.4%) significant drug-events, or 6 drug risks for both SJS and TEN (Figure 4.2B). Of
note, lamotrigine was only nominally significant and did not surpass drug risks outside of random
drug and event co-reporting. We found that significant drug-events were not enriched at any child
development stage but significant drug risks were more often greater at stages between early and
late childhood (Figure 4.2C,D).
SJS and TEN are considered to be non-immediate hypersensitivity reactions mediated by
cytotoxic T cells[191]. Three biological models of hypersensitivity are hypothesized in the field:
the hapten model, the p-i model, and the peptide repertroire model[188][192][193]. For example,
there was a report of SJS along with bile duct injury in a 6 year old patient by the drugs amoxicillin
and naproxene. It was hypothesized that these two drugs acted as incomplete antigens or haptens by
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binding keratin on bile duct cells that generated autoantibodies resulting in the disease state[194].
Genetic variation within major histocompatability complex genes is strongly associated to SJS, such
as HLA-B*15:02 allele[195]. There are other associated loci that regulate drug action in the body,
such as the CYP2C gene loci[196] and ABC transporters[197], that were associated with drug-
induced SJS/TEN. Using our resource, we evaluated associations between significant drug risks and
the expression of all the drugs’ gene partners and found ABCC4 (t-test FDR<4.6E-03), CYP3A4
(FDR<1.1E-07), SLCO2A1 (FDR<5.03E-10), and SLCO1B3 (FDR<1.93E-42) dynamic gene
expression significantly associated to SJS/TEN risk of its drug substrates across child development
stages (Figure 4.1E,F). Our findings corroborate ABC transporters as implicated in the genetic
susceptability of drug-induced SJS/TEN[197]. To further generate mechanistic hypotheses of
SJS/TEN drug risks, our resource makes available all drug-gene linkage information available,
scraped from Drugbank webpages, that can be leveraged to evaluate the role of molecular enzymes,
targets, and other gene products for drug-induced SJS/TEN (Figure 4.1G).
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Figure 4.2: Investigation of SJS/TEN drug-events. A) The number of reports for the drug and
adverse event co-occurrence across child development stages. B) The GAM risk log odds and the
number of drug-event reports (log10 transformed) for the significant, by the null model, drug-events.
C) The odds enrichment of significant serotonin syndrome drug-events at a child development
stage. D) The breakdown of significance for serotonin syndrome drug-events assigned within each
risk dynamics category. E) The average drug substrate risk for serotonin syndrome for each gene
sharing significant information (t-test FDR<0.01). F) The residual probe expression across child
development stages for the genes in B). G) The drug-gene linkage information for significant drug
risks extracted from drugbank webpages.
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4.4 Drug-induced Adrenal suppression
The Hypothalamic-pituitary-adrenal (HPA) axis is a neuroendocrine feedback system where
increased cortisol in the blood inhibits hormone production by the adrenal glands. It is reported
that during treatment with topical corticosteroids, excess cortisol absorbed into the body for long
periods of time can have a negative impact to this homeostatic system. After chronic exposure, the
HPA axis becomes suppressed such that endogenous cortisol production is attenuated and may take
months to recover to normal levels even after drug withdrawal[198]. The clinical manifestations of
the excess cortisol, or hypercortisolism, and subsequent adrenal suppression is called Cushing’s
syndrome[199]. Signs and symptoms of Cushing’s syndrome include accelerated weight gain, low
blood pressure, fat pads on the upper back, round cheeks or "moon face", hypercalcemia, and excess
facial hair growth[198].
Cushing’s syndrome is hypothesized to be a greater risk in infants and young children due
to their increased body surface to mass ratio[199][200]. Indeed, along with other factors such
as inflammatory state, Cushing’s syndrome is a greater risk because of increased absorption
into the bloodstream. Many of the published case reports of infants presenting with Cushing’s
syndrome included taking supraphysiological doses of potent topical corticosteroids for treating
dermatitis and eye infection[201]. However, topical corticosteroids are the standard of care per
recommended guidelines, with minimal side effects to treat skin diseases such as eczema during
childhood[202][203]. Moreover, other administered corticosteroids and medications also associate
with Cushing’s syndrome or hypercortisolism[199][198].
Using our resource, we investigated all drug reports for systemic effects noted in the literature:
Cushing’s syndrome, HPA axis suppression, and adrenal suppression. We identified the adverse
event MedDRA concepts for Cushing’s syndrome (OMOP identifier 35506447; N=85), HPA
axis suppression(OMOP identifier 43562908; N=7), and adrenal suppression (OMOP identifier
35506460; N=100) within Pediatric FAERS. There were 127 medications co-reported with these
adverse events. We observed 170 of these drug and events co-reported in Pediatric FAERS (Figure
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4.3A). There were 13 that were significant by our null model, such as clobetasol-Cushing’s syndrome
and mometasone-HPA axis suppression reported within the first year of life (Figure 4.3B). We found
that significant drug risks were more often greater at stages between early and late childhood and,
in fact, were enriched at the early childhood (odds ratio 4.36 [2.05, 8.23]), middle childhood (odds
ratio 4.36 [1.78, 8.46]), early adolescent (4.71 [2.00, 9.52]), and the late adolescent stage (odds ratio
3.23 [1.03, 7.70]; Figure 4.3C,D).
Corticosteroids are mostly metabolized by CYP3A4 enzymes in the liver and there glucocor-
ticoid receptor (NR3C1 gene) target regulates numerous downstream transcriptional programs
including inflammation, cell proliferation, and cytokine signaling in an age specific manner[75].
We find in addition to topical corticosteroids, antiretroviral and other medications were significant
drug risks that can be informative of downstream genetic players of this systemic adverse effect.
Using our resource, we evaluated associations between significant drug risks and the expression of
all the drugs’ gene partners and found 7 gene targets, carriers, transporters, and enzymes associated
with the risk of their drug substrates across child development (Figure 4.3E,F). From our resource,
we can propose hypotheses such as adrenal suppression drug risks associate with the expression of
the glycoprotein ORM1 gene product, which is expressed during an acute inflammatory state and
may be a potential drug safety endpoint for hypersensitivity reactions.
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Figure 4.3: Investigation of drug-induced Adrenal suppression drug-events. A) The number of
reports for the drug and adverse event co-occurrence across child development stages. B) The GAM
risk log odds and the number of drug-event reports (log10 transformed) for the significant, by the
null model, drug-events. C) The odds enrichment of significant serotonin syndrome drug-events at a
child development stage. D) The drug-gene linkage information for significant drug risks extracted
from drugbank webpages.
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4.5 Tetracycline versus beta lactam-induced tooth discoloration
The antimicrobial properties of tetracycline were discovered in 1945, where tetracycline was
then used to treat life threatening bacterial infections[204][205]. From a series of publications in
the 1950s and 1960s, however, tetracycline treatment was shown to result in tooth discoloration
and bone growth defects both transplacentally and when exposed to newborns, infants, and young
children[206][207][208]. Thus, the Food and Drug Administration issued a black box warning
in 1963 and the American Academy of Pediatrics issued guidelines in 1970 against the use of
tetracyclines in children under 8 years old because of tooth discoloration[209].
Tetracycline circulates through the body by binding to plasma proteins in the blood, is de-
posited in bone and tissue, and forms an irreversible tetracycline-calcium orthophosphate com-
plex[210][207][211][205]. The tetracycline flourophore has been observed within neonplasms,
bone, and teeth that can be seen after long periods of time dependent on the amount of tetracycline
oxidation[206][205]. There is evidence that other tetracyclines such as minocycline may also
provoke tooth discoloration by a similar mechanism[212].
Calcification of deciduous teeth (or colloquially called baby teeth) begins after the 4th month
of gestation to about 11-14 months of age. Calcification of the permanent teeth occurs after birth
through 7-8 years of age[213][207]. Calcification of the 2nd or 3rd molars is not complete until
16-18 years of age[208]. Importantly, and as one could imagine, teeth discoloration causes adverse
psychological effects in these children from having innocuous but discolored teeth[214].
Safer, alternative medications suggested are beta lactams, which are penicillin-like medica-
tions[204]. We investigated the evidence within our resource for differences in risk for teeth
discoloration in children (N=124 reports) between these two drug classes. We compare the risk
profile of tetracyclines (4 medications within the J01A ATC concept code) and beta lactams (7
medications under the J01C ATC concept code) drug risks associating with tooth discoloration
(OMOP concept identifier 35707667). Within Pediatrics FAERS, there was only one beta lactam,
amoxicillin, reported with tooth discoloration. On the other hand, there were three tetracyclines,
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Figure 4.4: Comparing tooth discoloration adverse effect risk between tetracycline and beta
lactam medications. The number of reports for the drug and adverse event co-occurrence across
child development stages. Above, The GAM risk log odds and the number of drug-event reports
(log10 transformed) for the significant, by the null model, drug-events.
including doxycycline, tetracycline, and minocycline, reported with tooth discoloration (Figure
4.4). We found only tetracycline was a significant drug risk for tooth discoloration by our random
association model, whereas amoxicillin and monocycline, but not doxycycline, were only nominally
significant drug risks (Figure 4.4). Our resource correctly identified known tetracycline drug risk,
with statistical evidence for heightened risk of tooth discoloration during early childhood or between
the ages of 2 and 5 years old. Our resource provided nominal evidence for previously reported
minocycline associated risk of tooth discoloration[205]. Three cases of amoxicillin-induced tooth
discoloration was reported by a physician at a Spanish health center (Amoxycillin-clavulanic acid-
related tooth discoloration in children). We found no evidence for doxycycline associated risk,
which aligned with a recent retrospective study that found no evidence of tooth discoloration in
children exposed to doxycycline during active tooth calcification[215].
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4.6 Montelukast-induced Psychiatric disorders
Inhaled corticosteroids are the first-line treatments for pediatric asthma shown to reduce symp-
toms, hospitalizations, and the need for rescue beta agonists, which rapidly open up lung airways
during an asthma attack[216]. However, inhaled corticosteroids have been associated with major
side effects including growth inhibition and adrenal suppression[217][218]. Alternatively, mon-
telukast is recommended for avoiding the labeled adverse effects of inhaled corticosteroids by
instead reducing inflammation and immune cell infiltration into airways[219]. A recent Cochrane
review showed improved asthma control by treatment with montelukast as an add-on therapy
to inhaled corticosteroids in adults[220]. Especially important for children, montelukast can be
ingested as a chewable tablet that makes it easier to take and adhere to compared to an inhaled
medication[221].
Montelukast is an antagonist of receptors that facilitate transport of leukotrienes, which play
a major role in the pathophysiology of asthma[222][219]. It was shown that daily treatment
with montelukast over a 12 week period significantly protected against exercised-induced asthma
compared with placebo in adults[223]. Montelukast is orders of magnitude more potent than
inhaled corticosteroids for asthma treatment, though less potent than beta agonists which rapidly
open up airways[221]. Unfortunately, montelukast treatment has been shown to result in rare
psychiatric adverse effects[224]. Montelukast adverse events were identified in 2005 after extracting
reports from the Xplain national prescription registrar, maintained by the Swedish drug sales
company Apoteket AB. The Food and Drug Administration also found increased reporting of
psychiatric adverse events as well, and presented heightened adverse event reporting trends by
children compared with adults[225][226][162]. Moreover, details from the report characterized
these adverse events occurring within a week of exposure, during usage of montelukast by itself,
and occurring mostly in younger children[225]. Initiation of montelukast treatment was reported by
both children and adolescents to result in reduced quality of life due to psychiatric adverse events
such as nightmares, temperamental behaviors, and sleep disorders[227].
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The mechanisms of montelukast-induced psychiatric adverse events is unknown[224]. Leukotrienes
are excreted by various types of cells including immune cells for promoting an inflammatory re-
sponse and immune infiltration[222]. When bound to leukotriene receptors, montelukast inhibits
leukotriene physiologic effects, such as airway edema, smooth muscle contraction, and impairment
of normal cellular activity, without exhibiting any agonist activity[228][229]. There is increasing
evidence of the presence of leukocyte receptors in the brain as well as its overexpression during
neuro- and other pathologic conditions[222][229][230]. Under nonpathological conditions, increas-
ing montelukast blockade in rat hippocampus cells in vitro resulted in increased proliferation of
neural stem cells and progenitors without affecting their identity and differentiation[231].
Using our resource, we investigated montelukast and other leukotriene receptor antagonists
for an association with psychiatric adverse events. We identified 540 psychiatric adverse events
and two leukotriene receptor antagonists, montelukast (Number of reports in Pediatric FAERS
N=7,013) and zafirlukast (N=22 reports). Out of 270 drug-events reported in Pediatric FAERS,
19 montelukast psychiatric adverse events were significant risks across child development stages
(only 1 of 11 observed zafirlukast psychiatric adverse events, sleep terror, was nominally significant
across child development stages) (Figure 4.5A). As we stated in our recent manuscript[232], we
found substantial evidence of montelukast drug risk for psychiatric adverse events across child
development stages.
We also explored an alternative mechanism for drug risks by the other montelukast target,
5-lipoxygenase (ALOX5). Arachidonic acid is catalyzed by enzymes such as 5-lipoxygenase that
regulate the metabolism of leukotrienes[233]. It was found that genetic variation in the promoter
sequence of 5-lipoxygenase results in a differential forced expiratory volume (FEV) in patients,
which was hypothesized to explain the variation in response to leukotriene receptor target antag-
onists[234]. A retrospective study found adult patients presented with asthma exacerbations and
FEV that strongly correlated with their ALOX5 genotype[235]. Furthermore, a prospective clinical
trial found montelukast treatment response was associated with patient ALOX5 genotype[236]. A
similar association was found for another 5-lipoxygenase antagonist, zileuton[237]. We therefore
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examined our resource for antagonists of ALOX5 and identified montelukast, as expected, and
two treatments of inflammatory bowel syndrome, sulfazalazine (N=429) and balsalazide (N=44)
(Figure 4.5B). There was one significant sulfazalazine risk for "Feelings of Worthlessness" (OMOP
identifier 36918952) and 2 significant balsalazide risks for "Middle Insomnia" (OMOP identifier
36718556) and "Periodic Limb Movement Disorder" (OMOP identifier 36516856; Figure 4.5C).
Considering all medications targeting ALOX5 and leukotriene receptors, we found significant
risk enrichment from one to five years old or during the toddler (odds ratio 4.14 [2.42,6.67] and
early childhood (odds ratio 3.31 [1.79,5.65]) stages (Figure 4.5D). While montelukast is the only
leukotriene receptor anatagonist, all three medications inhibit ALOX5 (Figure 4.5E; montelukast
was shown to inhibit ALOX5 in vitro and in mast cells in vivo[238]). We hypothesize that there is a
relationship between 5-lipoxygenase antagonism and risk for psychiatric adverse events, which may
coincide development of immune cell populations during early life[63].
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Figure 4.5: Investigation of montelukast-induced Psychiatric drug-events in our data-driven
resource. A) The GAM risk log odds and the number of montelukast-psychiatric event reports
(log10 transformed) for the significant, by the null model, drug-events. B) The number of reports
for the ALOX5-inhibitor drug and adverse event co-occurrence across child development stages.
C) The GAM risk log odds and the number of ALOX5 inhibitor-psychiatric event reports (log10
transformed) for the significant, by the null model, drug-events. D) The odds enrichment of
significant ALOX5 inhibitor-psychiatric event drug-events at a child development stage. E) The
drug-gene linkage information for significant drug risks extracted from drugbank webpages.
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4.7 The Pediatric Drug Safety portal (PDSportal)
We deployed a publicly-available web application to increase access by researchers for the thou-
sands of adverse drug event hypotheses within our resource. The goal of the Pediatric Drug Safety
portal (PDSportal; https://pdsportal.shinyapps.io/pdsportal/; https://github.com/ngiangre/PDSportal;
DOI: 10.5281/zenodo.5522816) is to make our generated database accesible to identify and evaluate
evidence for adverse drug events in the pediatric population. The PDSportal also provides download
links of our resource in total, which can be used to support analyses such as the previous compu-
tational investigations , as well as individual flat tables. The web application is a shinydashboard,
viewable on both desktop and mobile, and deployed using the shinyapps.io service by RStudio.
The PDSportal allows researchers to search and summarize available population-level evidence
of suspect medications for adverse events (Figure 4.6A). The portal prompts users to start selecting
concepts (main ingredients) for drugs from a dropdown menu displaying the drug name, ATC
code, and number of total drug reports in Pediatric FAERS (Figure 4.6B). Selecting drug reports
subselects for co-reported adverse events from a dropdown menu displaying the event name, system
organ class, and the number of drug reports co-reporting the event (Figure 4.6C). After pressing the
recently appeared ’Get population risk’ button (Figure 4.6D), progress retrieving the information
from the database is shown both as a completing-square in the top left corner and a progress bar
in the middle of the window (Figure 4.6E). After completion, the ’ADE report demographics’
tab displays multiple subplots and a larger graph of the number and percent of reports at each
development stage, including by reported sex, co-medication number and type, type of reporter,
and the date of reporting (Figure 4.6F-G). The ’ADE risk through childhood’ tab displays the log
odds risk for each drug-event pair against that for random drug-event reporting (shown in lightgray).
Moreover, a table of the log odds risk and number of reports for the drug-events at each stage is
available to copy or download (Figure 4.6H). Other tabs include ’About this app’ and ’Download
data’, and on the left side bar are collapsible boxes defining the age range for child development
stages, tips for using the app, relevant citations, and a disclaimer.
100
Figure 4.6: Pediatric Drug Safety portal (PDSportal): an accessible web application of ad-
verse drug events (ADEs) in the pediatric population. A) The web application landing page to
start selecting adverse drug events. B) The dropdown menu when selecting drugs. C) The dropdown
menu when subsetting for adverse events. D) The ’Get population risk’ button after selecting drugs
and adverse events. E) The progress indicators during the database retrieval. F) The ’ADE reporting
demographics’ summary subplots for all adverse drug event reports. G) The compilation summary
reporting figure in the ’ADE reporting demographics’ tab. H) The ’ADE risk through childhood’
summary plot and associated risk estimates table for each drug-event pair.
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4.8 Conclusion
In this series of case studies, we showed that our data-driven resource can be used to evaluate
clinically-relevant pediatric adverse drug events (ADEs). We examined known pediatric drug effects
with varying degrees of clinical and biological significance. We were able to encode these ADEs
within MedDRA and ATC standard concepts, examine risk estimates across child development
stages, estimate enrichment for risks during childhood, and form molecular and physiological
hypotheses for evaluation. Furthermore, we were able to take both a top-down, starting from
observations in the population, and bottom-up, starting from known drug pharmacology such as
antagonists, approaches to evaluate pediatric ADEs. We deployed the PDSportal web application
for promoting quick-and-easy access to population-level evidence for adverse drug event risk in the
pediatric population. For the first time, we provide a resource that improves both the identification
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Pediatric drug safety consistently considers children as small adults without incorporating the
unique biology of children[52][239][240]. This thesis presented novel informatics and systems
biology methods that harmonized identifying adverse drug events in children and evaluating pu-
tative mechanisms from biological growth and development. In addition, we highlight three key
research directions that build upon foundational pediatric research and discuss novel approaches for
improving pediatric drug safety (Figure 5.1).
5.1.1 Child versus adult drug safety profiles
A known but still unsolved problem is detection of adverse drug effects in children and their
comparison to adults[241]. Population stratification is a popular approach to identify adverse drug
effects within the pediatric population and was used to discover the arrhythmogenic effects of short-
acting beta-agonists from electronic health records[242]. In other applications, pediatric populations
are compared directly to adult populations, as was used to identify renal toxicity associated with
enalapril in EudraVigilance[243]. Recent work has started to refine these comparisons by comparing
across developmental stages[111][244]. The use of these detection methods, which are efficient and
essential for identifying drug-adverse event associations (see reviews on disproportionality measures
103
Figure 5.1: Three unsolved and critical research directions to enhance pediatric drug safety.
Novel informatics and systems biology approaches are needed to tackle both signal identification
and mechanistic evaluation of adverse drug effects in children. Observational databases are critical
for systematic analyses but inherent bias and confounding requires correction for producing sound
detection results. Mechanistic databases, such as Drugbank or Chembl, evaluate adverse drug effects
using biomedical and chemical knowledge to predict drug toxicities. Developed methodologies
require adequate internal and external validation to ensure method robustness and generalizable
results.
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and data mining[245][246]), are still burdened by potential confounding due to disease status, growth
considerations at drug prescription, and other extraneous factors. Methodologies must be nuanced
enough to distinguish differences in adverse effects from differences in prescribing and reporting
patterns. Moreover, fair and accurate comparisons of children to adults will potentially uncover
effects of pediatric-specific mechanisms. Real-world-data, like those found in electronic health
record databases, gather clinical data on large populations of patients as a byproduct of the practice
of medicine. As a result of their size, these resources can be used to identify less frequent but still
clinically-relevant adverse drug effects in children[247][248]. Additionally, analysis of real-world-
data can prioritize plausible ADEs from thousands of data-mined hypotheses, helping to identify
the needles in the adverse event haystack[249][250]. As automated and computational methods
become more commonplace, however, high quality reference sets are required. Methodologies
can be compared and evaluated against a common reference set, such as the one created by the
GRiP consortium[150]. Our lab developed a machine readable version of these data that is publicly
available to the research community[160]. Detection of adverse drug effects during childhood
through comparison to adults requires novel statistical approaches for sound population comparison
and corroboration within real-world-data and a pediatric-specific reference set.
5.1.2 Drug toxicity profile across childhood
Pediatric drug safety can be evaluated in the pre-marketing phases by focusing on adverse drug
reactions that may result from growth and maturation processes during childhood[241]. Systems
biology methods offer a way to extrapolate from the biology of developmental processes to the
clinical effects they may modulate in pediatric drug treatment. These methods can integrate
observational with mechanistic data, such as drug pharmacology in Drugbank[171] and drug
properties in Chembl[251], to study how mechanisms of development may lead to drug toxicity[252].
For example, researchers have linked observed ADEs to mechanisms, such as drug targets associated
with heart failure[253], target inhibition associated with renal disorders[130], and drug structures
associated with QT prolongation[254]. However, the biological mechanisms characterizing adverse
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drug effects during childhood require novel approaches that go beyond the guilt-by-association
hypothesis[255] and incorporate temporal and dynamic changes of biological networks. Time-series
based machine learning approaches can learn drug properties for predicting adverse reactions
across childhood, similar to Matlock et al. who developed a time-embedding algorithm to predict
CYP enzyme activity across childhood[256]. Quantifying the age-dependence of toxicities across
childhood would improve translation of effects during growth and maturation into development
stage-specific clinical trials and clinical contexts. Approaches for validation are critical when
developing these methodologies, including both internal validation for ensuring the method is
accurate and external validation for assessing generalizability to other drugs, adverse effects,
and clinical settings. Once validated, drug toxicity hypotheses would be powerful for further
investigation of metabolic, gene, and clinical markers for incorporation into pharmacometrics and
juvenile animal studies[257][258]. Systems biology and machine learning approaches can integrate
observations and mechanisms to predict potential drug toxicity across childhood.
5.1.3 Genetic susceptibility of pediatric adverse drug events
The genetic basis of adverse reactions from drug exposure remains largely unknown[50][259].
Genome wide association studies (GWAS) are established approaches that associate genetic poly-
morphisms with adverse drug reactions, such as anthracycline-induced cardiotoxicity in chil-
dren[260][261]. GWAS are limited, however, to understanding genetic contributors with single,
often common phenotypes[262] and lack the biological context that might be necessary to under-
stand drug-induced phenotypes. There is an opportunity to use systems biology to provide the
biological context needed to understand GWAS results of drug-induced phenotypes[263]. For exam-
ple, building long QT syndrome genetic networks showed enrichment of known gene variants from
GWAS likely to affect the QT interval[263] and the modular assembly of drug safety subnetworks
(MADSS) algorithm significantly improved detection of adverse drug reactions by incorporating
protein-protein interactions into adverse event neighborhoods[264]. In children, the growth and
developmental processes during childhood interact with genetic factors[265][116] and complicate
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direct associations with adverse drug reactions. Towards a similar problem, our research group
developed a methodology founded on hypothesized population-specific mechanisms addressing
statistical bias and confounding that uncovered thousands of ADEs, many with a potential basis
in genetics, showing increased safety risks in women[266]. Novel methodologies in pediatric
drug safety are tasked to unravel both genetic mechanisms and their dependencies across child
development to uncover pediatric-specific genetically-induced adverse drug effects.
5.2 Thesis Summary
This body of work contributes to building drug safety evidence primarily for children using a
data-driven approach developed for evaluating clinical and biological mechanisms. Historically,
medications were not developed for children, which categorized them as "therapeutic orphans", even
though the drug efficacy and safety laws of the 20th century manifested from tragedies affecting
children [267][268] [23]. Nonetheless, recent legislation at the turn of the 20th century, such as
the Best Pharmaceuticals in Children Act (BPCA) and the Pediatric Research Equity Act (PREA),
have regulated incentives and mandates of clinical trials for new drugs [20]. The FDA issued
industry guidelines for pediatric drug development in 2014 that initiated programs and institutes,
such as the Pediatric Trial Consortium, the Critical Path Institute, and the Institutional Development
Awards States Pediatric Clinical Trials Network (ISPCTN), that evaluate the efficacy and safety
of medications in children [269]. Despite these significant regulatory advances in pediatric drug
development, increasing the amount of pediatric clinical trials is not the only path to generating
drug safety evidence for children. In this thesis, I developed a pediatric drug safety framework that
integrates both detection and evaluation of pediatric drug effects.
In chapter 1, we surveyed the pediatric drug safety landscape and argued that children are
consistently considered as small adults. On the contrary, adults and children differ in large part
due to dynamic biological processes during child growth and development. Children taking
medications may experience an adverse effect resulting from interactions with dynamic biological
and physiological processes from birth through adolescence. Furthermore, medication effects may
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influence these biological processes resulting in adverse effects later in childhood or as adults.
Evaluating medication effects throughout childhood is outside the scope of clinical trials and thus
require a new study design and data source. Retrospective databases, such as the FDA Adverse
Event Reporting System, are a large scale source of evidence for adverse drug events (ADEs) and
are utilized to identify pediatric adverse drug effects[243][270]. Notwithstanding, pediatric drug
safety has been characterized by event monitoring and lacks clear subsequent steps to evaluate
ADEs in children. In chapter 2, we evaluated the ADE detection performance of a popular ADE
identification method, the proportional reporting ratio (PRR), to a logistic generalized additive
model (GAM). We found the GAM has at least similar overall performance with the PRR but
importantly improved power to detect adverse drug events in the pediatric population overall and
within development stages. The statistical hypothesis of sharing information by the GAM directly
corresponds with the biological hypothesis of shared information between child development stages.
Thus, using the GAM presents an opportunity to evaluate drug safety evidence in the context of and
in interaction with child development. Thus, we utilized hundreds of thousands of reports collected
by the Food and Drug Administration on adverse drug events experienced by children from birth
through adolescence, which we call Pediatric FAERS. In chapter 3, we developed a data-driven
approach using generalized additive models, including confounding mitigation, to systematically
estimate risk of nearly half a million adverse drug events in Pediatric FAERS. We found 20,000
significant drug-events across all stages of child development, where we found the frequency of
systemic disorders across childhood reflected mechanisms from pediatric developmental biology
and medication-specific risks for these systemic disorders. We evaluated the ADE risk estimates
across childhood and found co-incidence with gene expression dynamics of cytochrome P450
enzymes, suggesting our methodology captured biological underpinnings for the observed drug
risks. This study produced a rich resource of drug safety evidence in the pediatric population. In
chapter 4, we used the evidence provided within this resource to evaluate known, clinically-relevant
pediatric adverse effects. Additionally, we developed publicly-available web application called the
Pediatric Drug Safety portal (PDSportal) for easy access to our generated database. The PDSportal
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is an easy-to-use gateway to search the risk evidence and population demographics of adverse drug
events in the pediatric population in the context of child development; we also make available our
database for download. This thesis work lays the foundation for further data-driven pediatric drug
safety research, where we highlighted three research directions in the previous section.
In summary, our work developed an argument for the interaction between child developmental
biology and adverse drug effects and demonstrated that the evidence of medication risks in children
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